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Catheter-­associated  urinary  tract  infections  (CAUTIs)  are  the  most  common  health-­
care  associated  infections,  which  contribute  greatly  to  the  morbidity  and  mortality  
of  critically  ill  patients.  This  systematic  study  investigated  metal  organic  framework  
(MOF)   structures   in   the   forms   of   Zeolitic   Imidazolate   Framework-­8   (ZIF-­8)   and  
ZnO@ZIF-­8,   regarding   the   effects   of   synthesis   route   on   antimicrobial   ability   and  
their  incorporation  into  silicone  elastomer  composites.  The  conformability  (in  terms  
of  mechanical  properties)  of  each  embedded  composite  sample  was  assessed,  and  
comparisons  were  made  against  commercial,  dermatologically  tested  maxillofacial  
silicone.  
Two   ZIF-­8   materials   were   synthesised   in   organic   and   aqueous   media,  
correspondingly,  which  resulted  in  crystals  of  different  sizes  and  morphologies.  The  
ZIF-­8  (MeOH)  prepared  in  methanol  medium  at  room  temperature  resulted  in  60  
nm  spherical  nanoparticles.  The  ZIF-­8  (TEA)  prepared  in  aqueous  medium  in  the  
presence  of  triethylamine  (TEA)  at  room  temperature  contained  ca.  250  nm  cubic  
crystals.   The   two   samples   were   post-­synthetically   treated   with   silver   nitrate   to  
convert   into  ZnO@ZIF-­8  materials,  as  a  result  of  the  spontaneous  growth  of  ZnO  
nanorods  within   ZIF-­8.   Antimicrobial   ability   was   established   for   all   samples  with  
average  minimum  bactericidal  concentrations  (MBCs)  (mg/mL)  in  the  range  0.0228  
–  0.0709.  The  samples  were  incorporated  into  composite  silicone  samples  (4  wt.%  
of   biocide).   Introduction   of   ZnO-­nanorods   to   the   structures   increased   the  
antimicrobial  activity.    
Investigations   into   composite   mechanical   properties   showed   that   ZnO@ZIF-­8  
(MeOH)  interfered  with  the  curing  of  silicone  polymers  most,  despite  presenting  the  
lowest   MBC   (mg/mL).   With   regards   to   other   incorporated   ZIFs,   mechanical  
properties  of   the  composite   silicones  were  not  detrimentally  affected.  Successful  
biocidal   action   of   the   MOF-­loaded   silicones   was   demonstrated   using   the  
microbiology  method  BS  ISO  22196:2011,  against  the  model  bacterium,  Escherichia  
coli.   This   study   highlighted   the   significant   potential   of   antimicrobial   ZIFs   in   the  
development   of   biocide-­containing   catheters.   Incorporation   of   ZnO-­nanorods   in  
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CHAPTER  1:  INTRODUCTION  
Catheter-­associated   urinary   tract   infections   (CAUTIs)   are   amongst   the   most  
common   infections   acquired   in   the   healthcare   environment   worldwide.1,   2  
Colonisation  of  a  catheter  by  a  microorganism  can  result  in  biofilm,  often  causing  
blockages.3,  4  If  microorganisms  reach  the  patient,  infections  may  be  caused  -­  some  
of  which  are  becoming  more  difficult  to  treat  due  to  the  emergence  of  antimicrobial  
resistance.5,  6  Due  to  this,  the  development  of  catheter  materials  with  the  ability  to  
control   microbial   colonisation   is   much   needed   to   help   reduce   the   frequency   of  
antibiotic  treatments.    
Research   into  porous  materials,  such  as  zeolites,  ordered  mesoporous  silicas  and  
metal-­organic  frameworks  (MOFs),  has  identified  structures  with  large  surface  areas  
and   uniform   pore   sizes,   enabling   the   release   of   antimicrobials   and   thus   the  
demonstration   of   antimicrobial   activity.   Whilst   zeolites   and   ordered  mesoporous  
silicas  have  shown  drawbacks  regarding  low  drug-­storage  capacity,  alongside  too  
rapid  drug  delivery,7  MOFs  have  presented  promising  characteristics  and  properties  
suggesting   controlled   and   sustained   effects.8   Furthermore,   tuneable  MOF   crystal  
sizes,  ranging  from  the  nano-­  to  micro-­scale,  allow  for  the  variation  of  both  internal  
and  external  surface  areas.  Hydrophobic  MOFs  are  ideal  candidates  to  incorporate  
into  polymers  and  thus,  could  permit  composite  polymer  materials   to  have   long-­
term  antimicrobial  activity.  This  study  examines  the  antimicrobial  abilities  of  Zeolitic  
Imidazolate   Framework-­8   (ZIF-­8),   which   was   not   shown   to   have   antimicrobial  
activity,   and   of   ZnO@ZIF-­8   -­   a   highly   potent   antimicrobial,   as   demonstrated   by  
preliminary  studies.9  Various  sizes  of  ZIF-­8  were  prepared  and  tested  prior  to  post-­
synthesis   treatment   to   form  ZnO@ZIF-­8,   then   embedded   into   silicone   elastomer  
composite  samples.9  Antibacterial  activity  of  the  composite  samples  was  conducted  
using   BS   ISO   22196:2011,   and   mechanical   testing   ensued   to   monitor   material  
properties.    
The   successful   development   of   a   biocide-­embedded   silicone   would   hold   great  
potential   to   help   eradicate   CAUTIs.   Should   the  material   be   suitable   for   biocide-­
containing  catheters,  the  global  threat  of  increased  antimicrobial  resistance  would  
also  be  reduced.    
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1.1.  Metal  Organic  Frameworks    
Metal-­organic   frameworks   (MOFs)   are   an   exciting   class   of  materials,   offering   an  
ever-­expanding  scope  of   research.  Also  known  as  porous  coordination  polymers,  
MOFs   are   3D-­ordered   porous   materials,   composed   of   inorganic   metal   clusters,  
bridged   by   organic   linkers   such   as   carboxylates,   phosphonates,   or   nitrogen-­
containing   ligands.   In   certain   cases,   these   structures   exhibit   record-­setting  
Brunauer-­Emmett-­Teller  (BET)  surface  areas  that  can  be  as  high  as  ~7000  m2/g,  
compared   to   that   of   up   to   1000   m2/g   for   zeolites,   making   them   exceedingly  
favourable  for  their  potential  applications.10,  11  The  ultrahigh  porosity  of  MOFs  (up  
to  90%   free  volume),  has  been  unsurpassed  by  any  other  material,12  and   it  has  
been   demonstrated   computationally   that   MOF   materials   may   have   hypothetical  
surface  areas  as  high  as  ~14600  m2/g.10  The  discovery  of  these  properties  stems  
from  a  vast  number  of  research  papers  published  within  the  last  thirty  years,  which  
highlight  their  importance  and  depict  intriguing  crystalline  material  advances.12-­16    
Fundamentally,   structures   of   MOFs   combine   organic   with   inorganic   chemistry,  
interlinking  contrasting  disciplines  and  creating  a  plethora  of  topologically  diverse  
and   flexible   structures.   By   appropriately   selecting   their   organic   and   inorganic  
components,  MOFs  can  be  tailored  for  purpose,  e.g.   they  may  have  one,   two  or  
three   dimensional   structures,   incorporating   micro-­   or   meso-­sized   pores.17   Such  
structures  may  be  formed  with  or  without  open  metal  centers,  and  have  the  ability  
to   append   functional   groups   within   their   pores.18   Nanoscale   MOFs   in   particular  
exhibit  unique  physical  and  chemical  properties,  distinctly  due  to  their  corresponding  
bulk   materials.19,   20   The   design   of   MOF-­derived   nano-­structures   has   led   to   a  
recognition   of   the   importance   of   morphology   in   the   enhancement   of   MOF  
performance.21  When  compared  to  their  components  alone,  such  structures  display  
a   broader   range   of   external   surface   areas,   shapes   (tunnels,   cages,   etc.)   and  
abilities.22,  23    
The   design   of   target  MOFs  with   specific   properties   and   functions   has   become  a  
boundless  aspiration  for  scientists  from  a  variety  of  backgrounds.  Resultantly,  MOF  
synthesis  has  developed  a  plethora  of  different  synthetic  methods  and  strategies,  
though  typically  follows  a  solution-­mediated  reaction  process.24,  25  Despite  starting  
from   the   same   reaction   mixtures,   divergent   metal   organic   frameworks   can   be  
obtained   by   applying   a   variety   of   routes   and   conditions.26   Depending   upon   the  
intended   application   of   MOFs,   careful   thought   must   be   given   to   the   preferred  
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reaction  time,  yield,  temperatures,  particle  sizes  and  morphologies  -­  particularly  if  
the  intention  is  to  mass-­produce  the  MOF  on  a  large  scale.  Synthesis  routes  range  
from  conventional  to  systematic,  whilst  computational  and  alternative  routes  are  in  
continuous   development,   e.g.   microwave-­assisted,27   electrochemical,28  
mechanochemical29  and  sonochemical  syntheses.30  
Conventional  MOF  synthesis  refers  to  reactions  which  require  conventional  electric  
heating,   without   parallelisation   of   reactions.   It   may   be   refined   to   two   routes;;  
solvothermal   and   non-­solvothermal   synthesis.24   In   most   cases,   solvothermal  
synthesis   refers   to   reactions   occurring   under   autogenous   pressure,   above   the  
boiling   point   of   the   chosen   solvent,   within   a   closed   vessel.31   Non-­solvothermal  
synthesis  however,  refers  to  reactions  occurring  at  or  below  the  boiling  point  of  the  
solvent,  under  ambient  pressure.    
In   contrast,   non-­conventional  MOF   synthesis   can   entail   solvent   evaporation   of   a  
solution  of  reactants,  the  layering  of  solutions,  and  the  slow  diffusion  of  reactants  
into   each   other.   Drawbacks   exist   when   using   these   approaches   for   commercial,  
large-­scale  synthesis  and  harmful  and  environmentally  hazardous  organic  solvents  
are   regularly   required.   High   temperatures   and   long   reaction   times   are   often  
necessitated.  Where  sealed  and  pressurised  reaction  vessels  are  concerned,  high  
processing  costs  become  inevitable.32    
The  expertise  of  those  researching  MOFs  has  been  a  driving  force  for  alternative  
method  development.  Coordination  chemistry  has  accounted  for  the  introduction  of  
electrochemical   and   mechanochemical   syntheses,   as   well   as   concepts   like   the  
precursor  approach  or  in  situ  linker  synthesis.  First  reported  in  2005,  electrochemical  
MOF   synthesis   permits   a   continuous   process   with   the   possibility   of   obtaining   a  
higher   solids   content   than   those   gained   from   batch   reactions.24   It   has   become  
favourable  for  industrial  processes,  although  H2  is  regularly  formed  as  a  by-­product.  
Mechanochemical   synthesis   techniques   have   also   advanced,   whereby   reactions  
require   the   mechanical   breakage   of   intramolecular   bonds   to   permit   a   chemical  
transformation.   Initially   described   in   2006,   this   route   became   environmentally  
favourable  due  to  the  exclusion  of  organic  solvents.33  With  this,  metal  oxides  can  
be  replaced  by  metal  salts,  and  water  remains  as  the  only  side-­product.  The  process  
generally  produces  MOFs  of  small  particle  sizes,  requires  short  reaction  times  and  
provides  quantitative  yields  –  thus,  interest  surrounding  mechanically  activated  MOF  
synthesis  has  grown  rapidly.    
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Furthermore,  organic  chemistry  has  been  responsible  for  microwave-­assisted  MOF  
synthesis.  Microwave-­heating  is  a  well-­known  energy  source,  which  results  in  fast  
reaction  rates  and  short  reaction  times.  Due  to  quick  kinetics  of  crystal  nucleation  
and  growth,  high  product  yields  of  good  phase  purity,  and   few  or  no  secondary  
products,  such  routes  are  also  favourable.34  MOFs,  such  as  MOF-­5  and  IR-­MOF1,  
have  been  well-­characterized  this  way  and  large  quantities  of  such  frameworks  are  
successfully   isolated  over  economically-­viable  periods  of   time.27,  35  Much   focus   in  
this   field   has   surrounded   the   development   of   nano-­sized   crystallites,   which   are  
particularly  useful  in  functional  devices.    
For   most   MOF   syntheses,   reactions   occur   in   the   presence   of   a   solvent   at  
temperatures  ranging  from  ambient  to  ~250°C.  Heat  and  energy  can  be  generated  
by  multiple  means  leading  to  further  alternative  synthesis  routes.  These  may  utilise  
electric   potential,   electromagnetic   radiation,   mechanical   waves   (ultrasound),   or  
mechanical   methods   of   energy   input.36   The   duration,   pressure   and   energy   per  
molecule  within  the  system  is  directly  related  to  the  energy  source  provided,  which  
in  turn  influences  the  formation  of  the  product,  particle  size,  size  distribution  and  
particle  morphology.    
Consequentially,   the   MOFs’   properties   and   suitability   to   applications   may   be  
affected,  i.e.  there  may  be  a  direct  impact  on  catalytic  reactions  or  the  adsorption  
and   separation   of   molecules.   Today,   MOFs   are   almost   routinely   designable   to  
withstand  severe  physical  and  chemical  conditions.  MOFs  with  particularly  strong  
stabilities  are  often  used  as  heterogeneous  catalysts  in  chemically  harsh,  condensed  
phases,   as   well   as   in   thermally   challenging   conditions   relevant   to   gas-­phase  
reactions.18   Industrial   applications,   such   as  moderate-­temperature   storage,37   ion  
exchange38   and   gas   separation39   rely   on   chemical   (specifically   hydrolytic)   and  
thermal   stabilities.   Favoured,   compacted   MOF   forms   (such   as   pellets)   are   also  
required  to  be  mechanically  stable.40  Modern  advances  have  led  to  frameworks  with  
varied  combinations  of  mechanical,  thermal  and  chemical  stabilities.  However,  no  
single  MOF  with  perfect  stability  in  all  fields  currently  exists.    
Applications   of   MOFs   have   mostly   focused   on   clean-­energy   and   environmental  
protection.  Much  published  research  is  based  on  catalysis,  gas  storage,  separation  
and  carbon-­capture,  however  contemporary  advances  have  been  made  regarding  
their   integration  with   electronic   devices   and   chemical   sensors.41-­47   The   literature  
also   describes   MOFs   in   the   removal   of   toxic   industrial   chemicals   and   chemical  
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warfare   agents.48,   49   In   closer   relation   to   this   study,   advancements   have   been  
reported   in   biological   and   medicinal   MOF   applications   (e.g.   biomolecule  
encapsulation   and   drug   delivery).50-­52   These   are   of   particular   interest   when  
considering  the  development  of  MOFs  with  antimicrobial  ability.7,  53,  54  Overall,  the  
ultimate  aim   is  to  find  a  fast,  energy-­efficient  and  environmentally-­friendly,  room  
temperature   method,   that   can   easily   be   carried   out   on   a   mass   scale   for   the  
formation  of  any  MOF  structure  desired.    
  
1.2.  Zeolitic  Imidazolate  Frameworks    
Zeolitic   imidazolate  frameworks  (ZIFs)  are  a  tetrahedrally-­coordinated  subclass  of  
MOFs,  consisting  of  a  divalent  metal  cation  and  four   imidazolate  anion   ligands.55  
Composed   via   self-­assembly,   metal   ions   such   as   Zn2+   are   linked   through   the  
nitrogen  atoms  of  deprotonated  frameworks.56  They  possess  topologies  analogous  
to  zeolite  structures  and  are  most  easily  illustrated  by  their  sodalite-­type  cages.57,  
58   Like  MOFs,   ZIFs   have   tunable   pore   sizes   and   versatile   functionalities,   though  
typically   exhibit   greater   chemical   and   thermal   stabilities   than   traditional   MOFs  
alone.59  This   is   likely  due  to   increased  basicity   from  the   imidazolate-­type   linkers,  
which  depending  upon  their  position  and  bulkiness,  may  result  in  the  synthesis  of  
ZIFs  with  distinct  and  different  topologies.60  Such  topologies  often  show  similarities  
to   those   of   inorganic   zeolites,61   i.e.   rhodolite   (RHO),   sodalite   (SOD),   gmelinite  
(GME),  and  Linde  type  A  (LTA).62    
Whilst  tuning  the  functional  properties  and  pore  structures  of  ZIFs,  numerous  novel  
ZIF  topologies  and  compositions  have  been  developed.  These  are  suitable  for  uses  
in  gas  storage,  gas  separation  and  catalysis.62  In  chemical  separations,  ZIFs  have  
been  favoured  over  the  use  of  zeolites.  Milder  synthesis  conditions  are  required  and  
customisable   frameworks   allow   them   to   be   competitive   candidates   for   the  
production   of   high-­quality   membranes.63   These   extensively   explored   ZIF  
membranes   and   adsorbents   have   consequentially   emerged   as   a   new   family   of  
molecular   sieves   and   porous   structures;;   particularly   useful   in   controlled   drug  
delivery   systems   (DDS)64   and   energy-­efficient   separation   technologies.   Thus,  
investigations  are  now  focused  on  more  reliable  and  scalable  ZIF  manufacture.65  
Alongside  crystalline  ZIFs,  amorphous  ZIFs  have  been  obtained  from  their  crystalline  
counterparts  through  heating,66  pressurising,67  ball-­milling68  and  electrical  discharge  
procedures.69   Such   structures   have   also   been   explored   for   applications   in   guest  
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immobilization  and  drug  delivery.58  Due  to  their  distinct,  yet  similar,  structure  to  the  
parent  ZIF,  these  amorphous  frameworks  may  provide  a  platform  to  complement  
thin  film  membrane,  sensor  and  low-­k  dielectric  devices.58,  70  
Currently,  the  most  extensively  studied  ZIF  is  ZIF-­8  (Fig.  1).  
  
  
Figure   1:   Chemical   structure   of   ZIF-­8.   Blue   tetrahedra   depict   zinc-­
nitrogen  bonds,  whilst   the  orange  sphere  represents  ZIF-­8’s  open-­pore  
structure.  Image  taken  from  Redfern  et  al,  2018.9   
 
Formed  from  zinc  ions  tetrahedrally  coordinated  to  2-­methylimidazole  (Hmim),  ZIF-­
8  has  gained  considerable  attention  due  to  its  high  surface  area,  and  high  thermal  
(>550°C   under   N2),  mechanical   and   chemical   stabilities.60,   71   It   exists   as   a   SOD  
topology,   which   crystallises   in   a   cubic   lattice   (space   group   I43m)   with   a   lattice  
constant  of  16.992  Å.  ZIF-­8  houses  great   flexibility,  with  pore  cavities  of  11.6  Å  
accessible  through  theoretical  pore  apertures  of  ~3.4  Å.72  Due  to  the  ‘flip-­flopping’  
motion  of  ZIF-­8’s  linkers  however,  said  frameworks  realistically  possess  an  effective  
aperture  size  of  ~4.0  Å.73    
The  material  applications  of  ZIF-­8   lie   in  membrane-­based  gas  separation,  carbon  
dioxide   capture,   hydrogen   storage,   small   molecule   separation,   catalysis,   drug  
delivery,74-­77  and  as  a  cathode  material   for   lithium-­sulphur  batteries  (S@ZIF-­8).78  
Literature  has  recently  described  ZIF-­8  to  show  biocompatibility  and  non-­toxicity.79  
During   investigations,   its   use   as   a   potential   drug   vehicle   for   cancer   treatments  
showed  acid  responsiveness  and  moderate  biocompatibility.60,  80,  81    
Typically,  solvothermal  processes  are  used  to  form  ZIFs,  which  require  the  mixture  
of  a  highly  diluted  metal   salt  with  organic   ligands,  within  an  organic   solvent.  An  
autoclave  then  heats  this  mixture  to  temperatures  up  to  200°C.60,  71,  82,  83  Though  
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ZIF-­8   is  usually  prepared  by  similar  methods,   recent  publications  have  described  
more   environmentally-­friendly,   non-­solvothermal   and   aqueous   routes.   These  
methods  are  significantly  quicker  and  require  much  less  energy  consumption.84-­87  
Microporous   ZIF-­8   has   also   been   prepared   by   various   means   of   solvothermal  
syntheses,60  chemical  vapour  deposition  (CVD),88  and  steam-­assisted  conversion.89    
Adaptations  of  both  organic  and  aqueous  synthesis  routes  were  used  in  this  study  
to  rapidly  form  ZIF-­8  nanoparticles  of  different  sizes.  Both  colloidal  chemistry  routes  
were   conducted   at   room   temperature,   resulting   in   lowered   energy   consumption  
when  compared  to  the  most  common  solvothermal  methods.87,  90    
Now  vastly  cited,  Cravillon  et  al.  became  the  first  to  report  on  the  characterisation  
and  synthesis  of  a  nanoscale  ZIF-­8  material.90  This  organic  route  relies  upon  the  
combination  of  a  methanol  solution  of  Zn(NO3)2•6H2O,  into  a  methanol  solution  of  
2-­methylimidazole  (Hmim)  at  room  temperature.  An  approximate  ratio  of  1:8:700,  
of  Zn(NO3)2•6H2O,  Hmim,  and  MeOH  is  required  respectively.  The  resultant  ZIF-­8  
did  not  require  any  activation  or  auxiliary  stabilisation,  and  good  yields  of  single-­
phase,  rhombic  dodecahedron,  ZIF-­8  nanocrystals  were  obtained.90  This  fast,  non-­
solvothermal   method   required   much   less   time   and   energy   than   alternative  
syntheses,  offering  a  favourable  route  for  achieving  good  product  yields.  
By   further   refining   the   environmental   effects   of   ZIF-­8   production,   successful  
aqueous  synthesis  routes  have  developed.84,  85,  87   Investigations  have  focused  on  
the  resultant  ZIF-­8’s  crystallinity,  particle  size  and  morphology.87    Nordin  et  al.,  in  
particular,  have  built  upon  an  existing  aqueous  synthesis  route,  which  also  resulted  
in   rhombic   dodecahedron   nanocrystals.   This   method   refined   previously   detailed  
chemical  usage  and  increased  the  ZIF-­8  yield,  prior  to  investigating  the  control  of  
ZIF-­8  particle  size.85,  87  A  molar  ratio  of  1:6:500  of  Zn(NO3)2•6H2O:Hmim:H2O  was  
chosen,  with  ratios  of  triethylamine  (TEA)  added  to  the  Hmim  solution,  relative  to  
the  total  molar  amount  of  the  synthesis  solution.  The  ZIF-­8  product  was  collected  
after  30  minutes  via  centrifugation,  and  then  washed  with  deionized  water  prior  to  
drying.87  Yields  of  85%  resulted,  following  the  removal  of  any  impure  components.  
By  altering  the  ratio  of  TEA,  ZIF-­8  particle  size  could  be  controlled.  Adapting  this  
method   allowed  nanocrystalline   ZIF-­8   (of   particle   sizes   different   to   those   gained  
from  organic  means),  to  be  obtained  and  investigated.  Although  well-­documented,  
electrochemical,   mechanochemical   and   microwave-­assisted   synthesis   routes   for  
ZIF-­8,  were  not  used  within  this  study.  
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Properties  of  MOFs  (and  thus  ZIFs),  can  be  enhanced  or  altered  by  means  of  post-­
synthetic  modification   (PSM).   This   requires   the  modification   or   exchange   of   the  
metal   ion  and/or  the  organic  linker  of  the  framework,  following  synthesis.  Ligand  
molecules  may  be  post-­synthetically  replaced  and  other  linkers  may  be  incorporated  
into  MOFs  using  routes  known  as  solvent  assisted  linker  exchange  (SALE)  or  solvent  
assisted   linker   incorporation   (SALI).91-­93   Modifications   may   be   covalent   and/or  
dative,  and  are   responsible   for  many   recent  advances  within   the  MOF   field.  One  
significant  example  is  the  use  of  MOFs  for  the  adsorption  and  release  of  drugs.  Here,  
the  biodegradable  character  within  the  ZIF  can  be  modified  by  the  choice  of   the  
metal,  organic  linker  and  structure.12    
With  regards  to  ZIF-­8,  PSM  has  resulted  in  frameworks  with  enhanced  capabilities.  
Mesopores  can  be   introduced   to   the   framework  and   thus  promote  mass   transfer  
kinetics  within  the  ZIF-­8  structure.  Due  to  this,  the  size  and  diffusion  limits  of  the  
original  ZIF-­8’s  micropores  are  exceeded.78,  94    
More  pertinent  to  this  study  are  the  works  by  Wee  et  al.  and  Yang  et.  al.,  whom  
both  use  solutions  of  silver  nitrate  for  the  formation  of  ZnO@ZIF-­8  from  pure-­phase  
ZIF-­8  samples.95,  96  This  PSM  of  ZIF-­8,  conducively  generates  fixed  ZnO  nanorods  
within   the   ZIF-­8   matrix   (Fig.   2).   It   is   a   spontaneous   room   temperature  
transformation,   which   requires   the   suspension   of   ZIF-­8   nanopowder   in   a   silver  
nitrate  solution  of  53.7  mM  AgNO3,  made  with  a  1:6,  water:ethanol  solution.  This  
light-­sensitive  mixture  is  then  covered  and  agitated  overnight,  prior  to  removing  the  
product  by  centrifugation.  
  
Figure   2:   Schematic   diagram   representing   the   spontaneous   local  
transformation  of  ZIF-­8  into  the  ZnO@ZIF-­8  nanocomposite,  embedded  
with  ZnO  nanorods.  Image  reproduced  from  Redfern  et  al,  2018.9  
 
The   resultant   ZnO@ZIF-­8   must   be   washed   with   absolute   ethanol   and   dried   at  
ambient   temperature.95   ZnO   nanorods   are   particularly   well-­known   for   their  
antimicrobial  properties.97-­99  
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1.3.  Antimicrobial  Resistance    
Throughout   the   past   decade,   the   presence,   growth   and   effects   of   antimicrobial  
resistance  (AMR)  have  been  comprehensively  documented  worldwide.100  
Referring  to  those  active  against  a  range  of  pathogens,  i.e.  bacteria  (antibiotics),  
viruses   (antivirals),   fungi   (antifungals)   and   parasites   (e.g.   antimalarials)   -­  
antimicrobial  drugs  have  allowed  huge  advances  in  both  public  health  and  global  
agriculture.101-­103  
Although   resistance   to   antimicrobials   is   a   natural   occurrence,104   overuse   of   such  
drugs   has   caused   the   rate   of   resistance   development   and   its   affected   scope   to  
increase.105  As  a  result,  the  fight  against  life-­threatening  infectious  diseases  and  the  
availability   of   antimicrobial   prophylaxis   is   at   risk   of   significant   regression.  
Furthermore,  AMR  has  vast  economic  impact.  In  the  United  States  (US)  alone,  over  
two  million  infections  per  year  are  caused  by  pathogens  resistant  to  their  first-­line  
antimicrobial  treatments,  costing  the  US  health  system  20  billion  USD.106    
Undoubtedly,   drug-­resistant   infections   are   claiming   lives.   Each   year,   ~700,000  
fatalities  are  reported  globally  due  to  AMR  strains  of  common  bacterial  infections,  
tuberculosis   (TB),   human   immunodeficiency   virus   (HIV)   and   malaria.105   This  
includes  deaths  reported  of  patients  contracting  secondary  bacterial  infections,  e.g.  
from  Klebsiella  pneumonia  in  HIV  patients,  Escherichia  coli  (E.  coli)  in  TB  patients  
and  Staphylococcus  aureus  in  those  with  malaria.100  ‘Last-­resort’  treatments  known  
to  cause  severe  side  effects  are  now  being  used  more  readily.  In  the  case  of  the  
antibiotic  colistin,  for  example,  previous  prescription  was  avoided  due  to  associated  
kidney   toxicity.105  The  drug  has   since   re-­emerged  as  a   last-­resort  against  Gram-­
negative   bacteria   already   showing   resistance   to   other   drugs.   Unfortunately  
however,   colistin-­resistance   has   recently   been   reported   in   Gram-­negative   bacilli  
infections   and   in   these   cases,   alternative   antibiotic   treatments   are   not   currently  
available.107  
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1.4.  Catheter  Associated  Urinary  Tract  Infections    
Catheter-­associated  urinary  tract  infections  (CAUTIs)  are  the  second  most  common  
cause  of  hospital-­acquired  infections  worldwide.108  As  the  most  preventable  form  of  
health-­care   associated   infection,   they   cause   avoidable   morbidity   and   increased  
health-­care  costs  throughout  developing  and  high-­income  countries.109,  110  Despite  
this,  antibiotic  prophylaxis  of  asymptomatic  CAUTIs   is  not   recommended,  as  this  
may   increase   the   rate   of   AMR   without   eradicating   pathogenic   bacteria.   Most  
commonly  used   in   ‘at   risk’  persons,   i.e.  hospitalised  and  post-­operative  patients,  
and   those  with  urinary   incontinence   (UI)   -­  most   frequently   shown   in   the  elderly  
population,  urethral  catheters  are  regularly  positioned  long-­term.111  It  was  reported  
in  1997,  that  100%  of  patients  developed  a  bacterial  urinary  tract  infection  within  
30  days  of   long-­term  catheterisation.112  This  was  reflected  by  an  estimated  total  
cost  to  the  UK’s  National  Health  Service  of  £1.4  billion  each  year,  in  UI  treatment  
alone.111,  113      
Urethral  catheters  have  been  used  for  more  than  3500  years,  allowing  the  drainage  
of  urine  on  an   intermittent  or   indwelling  basis.114  Though  developed  significantly  
throughout   the   20th   Century,   little   modification   has   been   made   since   the  
introduction   of   the   ‘closed’   catheter   system   in   the   1960s.115   With   this,   urine   is  
drained  through  a  tube  and  into  a  fused  receptacle.  A  contained  environment  for  
the   urine   results,   protecting   it   from   the   contaminated   environment.   The   space  
between   the   external   catheter   and   the   urethral   mucosa,   however,   offers   the  
opportunity   for  direct  pathogenic  entry  to  the  bladder.  This   is   the  most  common  
route  of  bacterial  entry.116  Bacteria  such  as  Proteus  mirabilis  are  urease-­producing.  
When  present,  urase  hydrolyses  urea  and  generates  ammonia,  which  increases  the  
pH  of  the  urine  and  leads  to  the  formation  of  hydroxyapatite  and  struvite  crystals.  
As   these  crystals  grow,  the  catheter  becomes  coated  by  the  crystalline  deposits,  
allowing  bacteria  to  attach  and  multiply.  This  often  limits  the  efficacy  of  antimicrobial  
coatings,  since  contact  with  the  underlying  protective  coating  is  reduced.117  Within  
24  hours,  bacteria  present  in  the  catheterised  urinary  tract  are  able  to  multiply  to  
high  concentrations.118  Biofilm  growth  on  both  the  inner  and  outer  catheter  surfaces  
is  common,  especially  if  crystal-­coated.  This  entails  the  cultivation  of  a  structured  
community   of   microorganisms,   which   then   becomes   encapsulated   within   a   self-­
developed  polymeric  matrix.117  The  biofilm  adheres  to  the  catheter  lumen,  becoming  
incredibly   difficult   to   eradicate   since   antibacterial   agents   are   often   unable   to  
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penetrate   the   biofilm’s   full   depth.4,   119   Once   symptomatic   CAUTIs   are   shown,  
systemic  antibiotics  are  employed,  bacterial  resistance  increases  in  cases  of  biofilm  
formation   however,   and   often   secondary   ailments   arise   requiring   further  
treatments,  e.g.  chronic  bacterial  prostatitis.117    
Thus,  the  development  of  antimicrobial  catheter  materials  with  the  ability  to  control  
microbial   colonisation  would   be   greatly   beneficial.   Current   practice   recommends  
treating  only  symptomatic  CAUTIs  with  antibiotics,  unless  cases  of  pregnancy,  pre-­
urological   surgery,   or   patients  with   high   risks   of   serious   infectious   complications  
with   strains   causing   a   high   incidence   of   bacteraemia   (e.g.   Serratia  marcescens,  
Escherichia  coli  and  Proteus  mirabilis),  are  shown.120,  121    
A  variety  of  efforts  to  modify  catheter  materials  and/or  their  surface  properties  have  
been  made.  The  hope  is  to  prevent  or  effectively  delay  biofilm  formation  and  thus  
prevent,  or  delay,  the  onset  of  CAUTIs.    
Silver   alloy-­coated   latex   catheters   and   nitrofural-­impregnated   silicone   catheters  
have  indicated  the  inhibition  of  urinary  pathogens.122  However,  despite  their  ability  
to   reduce   the   bacterial   contamination   of   urine,   their   actual   usefulness   against  
symptomatic   CAUTI   was   uncertain.123   It   has   also   been   concluded   that   CAUTI  
incidence  is  greater  in  male  catheter  users,  but  that  infection  is  more  frequent  when  
latex  materials  are  positioned  in  place  of  silicone  ones.124    
Research   into   surface   modifications   to   alter   hydrophobicity   and   the   creation   of  
antiadhesive  surfaces  (e.g.  heparin  and  phosphorylcolin),  has  also  been  made.120  
Unfortunately,  their  long-­term  efficacy  could  not  be  proven.117  
The   development   of   an   antimicrobial   agent   effective   against   bacteria   in   CAUTI-­
causing  biofilms  is  an  ultimate  goal  and  an  optimal  catheter  material  or  coating  is  
still  awaited.  Benefits  of  such  an  accomplishment  would  not  only  positively  affect  
the  economy  and  healthcare  sector,  but  also  aid  the  patients  concerned.  At  present,  
the   most   effective   methods   of   CAUTI   prevention   are   to   avoid   unnecessary  
catheterisation  and  to  remove  catheters  as  soon  as  possible.120  
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1.5.  Antimicrobial  Applications  of  Metal  Organic  Frameworks  
Research  into  the  antimicrobial  applications  of  metal  organic  frameworks  remains  
in  its  infancy.  Due  to  their  highly  functional  and  tailorable  make-­ups,  antimicrobial  
properties  may  result  from  the  MOF’s  composition,  structure  and/or  its  vast  internal  
volumes.  When  considering  a  MOF’s  organic  linkers,  ligands  may  be  chosen  which  
are   biologically   active   and/or   already   known   to   display   antimicrobial   activity.  
Reservoirs  within  the  framework  can  also  provide  spaces  in  which  guest  molecules  
may  be  incorporated.8  These  guests  alone  are  often  antimicrobial,  and  are  regularly  
comprised  of  metal  ions  or  oxides,  e.g.  silver  (Ag2+),  zinc  (Zn2+),  zinc  oxide  (ZnO),  
copper   (Cu+  or   Cu2+)   or   nickel   (Ni2+).   The   MOF   structure   may   biodegrade,   and  
antimicrobial  components  may  be  gradually  released  via  a  constant  mechanism.  If  
this  occurs  with  a  sustained  effect,  and  if  both  the  ligand  and  guest  molecules  are  
antimicrobial,  a  combination  of  biocidal  properties  may  result  in  synergistic  effects.  
The   combination   of   antibacterial   substances   and   gases,   e.g.   nitric   oxide   (NO),  
demonstrates  this.  Within  mammalian  biology,  NO  plays  a  key  biological  role  as  a  
signaling   molecule   though   is   also   known   to   be   toxic   in   excess   amounts.   When  
released  from  a  MOF,  localised  (as  opposed  to  systemic)  effects  occur.  Using  MOFs  
such   as   M-­CPO-­27,   allows   NO’s   controlled   release.   Due   to   the   behavior   of   the  
adsorption-­storage-­delivery   cycle,   unwanted   side   effects   observed   in   previously  
trialed  methods  can  be  avoided.  These  methods  used  zeolites  and  functionalised  
silica   nanoparticles   as   NO   delivery   vehicles,   though   led   to   the   production   of  
carcinogenic  and  pro-­inflammatory  side-­products.7,  125-­127  MOFs  are  also   favoured  
over  metal-­ion   loaded  natural   and   synthetic   polymers   due   to   their   uniformity   of  
speciation   and   their   distribution   of   metal   active   sites.   Furthermore,   the   strong  
stability  of  MOFs  in  the  presence  of  oxygen  and  water  inspires  their  potential  for  
use   in   antimicrobial   dermatology.   MOFs   could   be   applied   as   excipients   in   the  
preparation   of   topical   bactericidal   formulations   or  may   act   as   active   ingredients,  
which   improve   their   adhesion   and   penetration.8   Their   controlled   and   prolonged  
molecule   release  could   then   improve   that  of  poorly  absorbing  substances,  which  
otherwise  require  multiple  applications  to  achieve  and  maintain  a  sufficient  activity  
level.    
When  considering  the  immobilisation  of  MOFs  on  different  materials,  e.g.  silicones  
or   textiles,   new   promising   antimicrobial   products   may   be   developed.   Novel  
investigations   have   described   the   antimicrobial   potential   of   post-­synthetically  
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modified  ZIF-­8.9,  128  Redfern  et  al.  in  particular,  outlined  the  potential  of  ZnO@ZIF-­
8  against   common  CAUTI-­causing  pathogens,   finding   that  0.8  mg  mL-­1  ZnO  was  
required   to   exhibit   an   antimicrobial   effect,   whilst   ZIF-­8   exhibited   no   bactericidal  
ability  alone.  When  combined  to   form  ZnO@ZIF-­8,  an  MBC  of  0.25  mg  mL-­1  was  
obtained  and  the  MOF  demonstrated  the  ability  to  reduce  the  number  of  living  cells  
in  each  bacterial  biofilm  tested  to  below  the   limit  of  detection  (BLD,  a  6  to  8  log  
decrease  compared  to  exposure  to  control  solution),  over  a  24  hour  period,  at  the  
highest   tested   concentration   of   2   mg   mL-­1.   When   incorporated   into   silicone  
elastomers,  varied  levels  of  antimicrobial  action  were  observed  across  a  range  of  
CAUTI-­causing  pathogens.  It  was  stated  that   if  ZnO@ZIF-­8   is  able   to  prevent  or  
delay  bacterial  growth  on  silicone  material,  the  effect  on  consequent  CAUTIs  could  
be   significant.9  Nigar   and  Deniz   however,   investigated   the   bactericidal   effects   of  
polyurethane/ZIF-­8   (PU-­ZIF-­8)   coated   fabrics   against   Staphylococcus   aureus,  
concluding   that   PU-­ZIF-­8   nanocomposite-­coated   polyester   fabrics   had   both  
antibacterial   abilities   and   mechanical   stability.9,   128   Development   of   antibacterial  
wound   dressings   and   medical   devices   could   help   benefit   the   medical   industry  
significantly.9,  129  In  these  cases,  the  antimicrobial  material  should  also  prevent  the  
adhesion  of  bacteria  to  surfaces,  thus  preventing  biofilm  formation.    
Post-­synthetic  modification  of  MOFs  may  enhance  any  biocidal  capabilities  of   the  
original  structures  alone.130-­132  In  the  case  of  ZnO@ZIF-­8,  ZnO  is  already  broadly  
accepted  to  house  antimicrobial  abilities.  Combining  this  with  ZIF-­8  at  a  nanoparticle  
size,  houses  the  potential  for  developing  a  notable  biocidal  material.  Recent  work  
investigated   this   and   also   provided   evidence   of   non-­toxicity.   The   antimicrobial  
potential  of  the  precursor  ZIF-­8,  or  any  potential  mechanisms  of  action,  however,  
were  not  discussed.9  Despite  this,  Yamamoto  and  Zhang  et  al.  have  both  suggested  
antimicrobial   mechanisms   for   ZnO   nanoparticles.133,   134   Yamamoto,   used  
Staphylococcus  aureus  and  Escherichia  coli  to  examine  the  antibacterial  properties  
of  various-­sized  ZnO  nanoparticles.  It  was  stated  that  antibacterial  activity  increased  
as  the  ZnO  particle  size  decreased,  since  hydrogen  peroxide,  H2O2,  was  generated  
from  water  on  the  ZnO  surface  active  centers.  Facile  penetration  of  H2O2,  through  
the  bacterial  cell  walls,  caused  damage  to  their  structure  and  resulted  in  cell  lysis.133  
In  the  case  of  urinary  catheterisation,  it  may  be  possible  for  the  same  mechanism  
to  occur  within   the  catheter   tubing.  Furthermore,  as  bacteria  are  destroyed,   the  
outward  flush  of  patient  urine  may  help  prevent  or  reduce  biofilm  formation.  Zhang  
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et  al.   reported  a  similar   trend,   though  established  that   the  concentration  of  ZnO  
particles  was   the   primary   factor   responsible   for   biocidal   activity,   rather   than   the  
particle  size  of  ZnO.134  
Investigations  into  ZIFs  with  antimicrobial  effects  have  also  suggested  alternative  
biocidal  mechanisms.  With   regards   to   post-­synthetically  modified   ZIF-­8,   the   ZIF  
structure  reportedly  collapses  to  provide  a  sustained  antibacterial  effect  and  high  
durability.56   Zn2+   ions   are   gradually   released,   and   metal   agglomeration   and  
oxidation  are  prevented.  This  is  seen  in  the  case  of  ciprofloxacin  (CIP)  -­loaded  ZIF-­
8  (CIP-­ZIF-­8).  Here,  antibacterial  action  results  from  the  gradual  degradation  of  the  
ZIF-­8   structure,   and   the   release   of   Zn2+   ions   and   CIP,   resulting   in   the   physical  
destruction  of   the  bacterial   cell  wall.8,   56  Since  a  combination  of   the  mechanisms  
outlined  above,  may  apply  to  ZnO@ZIF-­8,   it   is  plausible   that  modified  MOFs  and  
ZIFs   house   extraordinary   antimicrobial   advantages   over   metal/metal   oxide   NPs  
alone.  Such  materials  would  find  a  wide  range  of  clinical  applications  and  recently,  
a   patent   has   been   granted   involving   the   development   of   antimicrobial   coatings  
formed  from  ZIFs.135    
  
1.6.  Silicone  Polymers  for  Medical  Use    
Synthetic  polymers  with  basic  repeating  units  of  “siloxane”  are  generally  categorised  
as   silicones.136   “Siloxane,”   refers   to  units  of  silicon   to  oxygen  bonds,  with   silicon  
atoms   bonded   to   organic   groups.   The   most   common   of   these   is  
polydimethylsiloxane  (PDMS),  whose  structure  sees  two  methyl  groups  bonded  to  
each   silicon.137   Due   to   the   combination   of   an   inorganic   backbone   and   organic  
branches,   silicones   house   unique   properties,   e.g.   chemical   and   thermal   stability,  
hydrophobicity   and   low   surface   tension,   making   them   particularly   durable   and  
biocompatible.138  As  such,  silicones  may  be  used  as  compounds,  fluids,  emulsions,  
resins,   and   elastomers  with   abounding   applications   across   diverse   fields,   having  
been  commercially  available  for  use  in  medical  applications  since  1946.136,  139      
Elastomers  of  silicone  are  amorphous,  viscoelastic  polymers,  formed  by  means  of  a  
cross-­linking  reaction,  allowing  the  formation  of  chemical  bonds  between  adjacent  
chains.  This  results  in  a  three-­dimensional  network,  usually  achieved  by  one  of  three  
main  methods:  cross-­linking  with  radicals,  cross-­linking  by  condensation  or  by  cross-­
linking  by  addition.136  Composites  in  this  project  were  formed  using  a  platinum  (Pt)  
catalyst.  This  resulted  in  cross-­linking  by  addition  in  order  to  exhibit  properties  such  
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as   flexibility   and   durability,   suitable   for   use   in   urinary   catheterisation.  Generally,  
elastomers  contain  extremely  weak  inter-­molecular  forces  and  have  a  low  Young’s  
modulus,  alongside  a  high  failure  strain,  in  comparison  to  other  materials.139    
In  this  work,  cross-­linking  was  achieved  by  reacting  vinyl  end-­blocked  polymers  with  
Si-­H  groups  carried  by  a  functional  oligomer  (Fig.  3).  Addition  mostly  occurs  on  the  




Figure  3:  Mechanism  showing  the  oxidative  addition  of  the  ºSi  to  the  Pt,  
H  transfer  to  the  double  bond,  and  reductive  elimination  of  the  product.  
To  simplify,  other  Pt  ligands  and  other  Si  substituents  have  been  omitted.  
Image  adapted  from  Colas  and  Curtis,  2004.136  
  
This   method   produces   accurately   moulded   pieces   of   silicone   without   shrinkage,  
however  caution  is  required  as  the  Pt  catalyst  may  bond  readily  to  electron-­donating  
substances  (such  as  amines),  to  form  stable  complexes  with  these  “poisons”.  This  
would  render  the  catalyst  inactive  and  inhibit  the  cure.  Platinum  cure  cross-­linking  
by  addition  is  commonly  used  for  the  development  of  precise  silicone  parts.136  
Furthermore,   most   silicone   elastomers   incorporate   “filler”.   This   acts   as   both   a  
material   extender   and   reinforcement   to   the   cross-­linked   matrix.   Without   it,   the  
resulting   silicone   polymer   would   be   weak   and   often   unsatisfactory   for   most  
applications.140  For  elastomers  with  medical  applications,  fumed  silica  remains  the  
filler  of  choice,  and  reinforcement  results   from  polymer  adsorption  by  the  silica’s  
large   surface   area.  Hydroxyl   groups   on   the   filler’s   surface   form  hydrogen  bonds  
between  the  filler  and  the  silicone  polymer,   thus   leading  to  elastomers  with  high  
tensile  strengths  and  elongation  capabilities.136    
By  adding  reinforcing  fillers,  silicone’s  stickiness  is  reduced,  hardness  is  increased,  
and  mechanical   strength   is  enhanced.  The   tiny   spheroid   silica  particles   (~10  nm  
diameter)   fuse   irreversibly   whilst   semi-­molten,   and   form   aggregates.136   These  
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incorporation  of  silica   filler   into  silicone  polymers   increases  the  polymer’s  already  
high  viscosity  and  is  widely  known  as  “compounding”.    
Previous  studies  successfully  incorporated  2  wt.%  and  4  wt.%  ZnO@ZIF-­8  within  
maxillofacial   silicone,   M511   (Technovent,   UK),   and   demonstrated   varied  
antimicrobial   efficacy   against   common   CAUTI-­associated   pathogens.9   The  
mechanical  properties  of  these  composite  silicone  elastomers  were  not  investigated.    
  
1.7.  Aims  and  Objectives    
The  aim  of  this  study  was  to  incorporate  antimicrobial  porous  materials,  in  the  form  
of   ZIF-­8s,   into   silicone   composite   samples,   then   determine   their   ability   to   kill   a  
CAUTIs-­  relevant  pathogen,  E.  coli.  
ZIF-­8  structures  of  different  particle  sizes  were  to  be  prepared  by  both  organic  and  
aqueous  syntheses,  prior   to  modification  and   investigation   into  their  antibacterial  
ability.   These   materials   would   be   characterised   by   techniques   such   as   X-­Ray  
diffraction  (XRD),  Scanning  Electron  Microscopy  (SEM)  and  Brunauer-­Emmett-­Teller  
(BET)   surface   area  measurements,   in   order   to   qualitatively   determine   their   size,  
structure  and  characteristics.    
Selected   ZIF-­8   samples   would   then   be   post-­synthetically   modified   by   AgNO3  
treatment  for  further  studies.  This  resulted  in  the  preparation  of  ZnO@ZIF-­8,  which  
also   required   characterisation.   Samples   of   each   precursor   ZIF-­8   were   kept   for  
comparison.  
Antibacterial   activity   of   ZIF-­8   and   ZnO@ZIF-­8   structures   would   be   screened   by  
means  of  minimum  bactericidal  concentration  assays.  Selected  ZIF  samples  were  
then  incorporated  into  composite  silicone  elastomers  containing  4  wt.%  of  biocide.  
The  antibacterial  activity  of  ZIF-­8-­  and  ZnO@ZIF-­8-­loaded  silicones  would  then  be  
assessed,  using  BS   ISO  22196:2011,   to  determine   their  potential  use  as  biocidal  
additives   to   polymers.   Their   conformability,   in   terms   of   mechanical   properties,  
would  be  evaluated.  
Inductively  Coupled  Plasma  Mass  Spectrometry  (ICP-­MS),  would  then  qualitatively  
determine   any   Zn-­release   concentrations   of   both   powdered   and   embedded   ZIF  
samples,   following   a   prolonged   period   of   incubation.   The   remaining   powdered  
samples  would  then  be  re-­characterised  by  XRD.    
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CHAPTER  2:  EXPERIMENTAL  
  
2.1.   Synthesis  of  ZIF-­8  and  ZnO@ZIF-­8  
Synthesis  of  ZIF-­8  and  ZnO@ZIF-­8  was  achieved  through  both  organic  and  aqueous  
routes.    
Organic   synthesis   for   ZIF-­8   was   achieved   through   an   adaptation   of   methods  
reported   by  Cravillon   et   al,  whom   stated   an   approximate  molar   ratio   of   1:8:700  
when  Zn(NO3)2:Hmim:MeOH  was  used.90    
Typically,   2.933  g  of  Zn(NO3)2•6H2O  and  6.4893  g  of  2-­methylimidazole   (Hmim)  
were  each  dissolved  in  150  cm3  of  the  organic  solvent  chosen  (methanol  (MeOH),  
industrial   methylated   spirit   (IMS)   or   N,N-­Dimethylformamide   (DMF)).   The   latter  
clear  solution  was  then  poured  into  the  former  clear  solution,  under  vigorous  stirring  
using  a  magnetic  bar.  Spontaneous  formation  of  a  milky  solution  was  observed  on  
mixing  and  stirring  was  ceased  after  1  hour.  The  resulting  solid  was  then  separated  
from   the  by  centrifugation  at  6000   rpm  for  10  minutes  and  washed   thrice  using  
fresh  MeOH  and  centrifugation  each  time.  To  ensure  sufficient  washing,  the  product  
was  ultrasonicated  until  complete  redispersion  was  observed,  prior  to  centrifugation.  
The  product  was  dried  overnight  in  an  oven  at  80°C.    
In  another  method,  ZIF-­8  was  prepared  using  an  aqueous  system,  which  required  
various  volumes  of  triethylamine  (TEA).  This  method  was  modified  from  Nordin  et  
al.87,  whereby  a  molar  ratio  of  1:6:500  of  Zn(NO3)2:Hmim:H2O  was  used.    
Typically,  2.00  g  (6.72  mmol)  of  Zn(NO3)2•6H2O,  was  dissolved   in  20  wt.%  total  
deionised  water  (12.11  g),  whilst  simultaneously,  3.312  g  (40.43  mmol)  of  Hmim,  
was  dissolved  in  the  48.45  g  deionised  water  remaining.  The  following  volumes  of  
TEA  were  then  added  to  the  Hmim  solution,  each  in  separate  reactions:  1  cm3,  2  
cm3,  3  cm3,  4  cm3.    
Both  solutions  were  then  stirred  vigorously   for  30  minutes  at  room  temperature.  
The  product  was  then  collected  by  centrifugation  at  3000  rpm  for  30  minutes,  then  
washed  repeatedly  with  deionised  water,  ultrasonication  and  centrifugation  until  a  
neutral  pH  was  shown.  Universal  indicator  paper  was  used.  The  remaining  solid  was  
then  dried  overnight  in  an  oven  at  60°C.  
All   samples   were   characterised   (as   detailed   below   in   2.2.),   in   order   to   confirm  
product  purity  before  proceeding  to  form  ZnO@ZIF-­8  structures.    
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Once   confirmed   pure,   ZnO@ZIF-­8   was   formed   from   the   ZIF-­8   by   the   following  
means,  regardless  of  the  prior  synthesis  route:  
A  solution  of  silver  nitrate,  AgNO3  (53.7  mmol)  was  made  in  Milli-­Q  ultrapure  water:  
ethanol  (v/v  =  1:6).    
1.00   g   of   ZIF-­8  was   then   added   to   35.00   cm3  AgNO3   solution,   in   a   foil-­covered  
beaker  and  stirred  continuously  for  12  hours.  The  resulting  solid  was  then  separated  
by  centrifugation  at  6000  rpm  for  40  minutes  and  washed  four  times  using  absolute  
ethanol  (200  mL  total  volume)  and  centrifugation,  each  time.  To  ensure  sufficient  
washing,  the  product  was  ultrasonicated  until  complete  redispersion  was  seen.  The  
product  was  air-­dried  in  a  fume  cupboard  at  room  temperature  and  pressure.    
  
2.1.1.  Upscaling  synthesis  
Throughout   this   project   the   syntheses   of   neither   ZIF-­8,   nor   ZnO@ZIF-­8,   were  
scaled-­up  systematically.  Instead,  multiple  reactions  following  the  synthesis  routes  
and   conditions   detailed   above   were   established   in   tandem,   with   the   aim   of  
producing  a  combined  batch  for  each  required  sample.  In  total,  32  reactions  were  
conducted  for  the  organic  (MeOH  only)  synthesis  method,  yielding  a  total  of  20.17  
g   ZIF-­8.   15   aqueous   reactions,   each   using   3cm3  TEA,  were   required   to   produce  
25.89  g  ZIF-­8.  In  turn,  10  reactions  for  each  form  of  ZnO@ZIF-­8  (both  synthesis  
route)  were  run,  producing  6.02  g  and  7.36  g  of  ZnO@ZIF-­8,  respectively.      
  
2.1.2.   Calcining  products    
All  MOF  compounds  used  in  further  investigations  were  ground  with  a  pestle  and  
mortar,   then   subject   to   calcining   by  means   of   continuous   heat   (200°C),   for   five  
hours,  in  air.  This  was  conducted  in  an  oven,  at  a  heating  rate  of  10°C/min.  This  
aimed   to  evacuate  guest-­molecules   from  samples   formed  using  TEA,  which  may  
have  been  trapped  within  each  structure’s  pores.  ZIF-­8  formed  using  methanol   is  
reportedly  guest-­free.90  
  
2.2.   Characterisation  of  Samples    
All  samples  were  ground  finely,  using  a  pestle  and  mortar,  prior  to  characterisation.  
In   preparation   for   analysis   by   Scanning   electron  Microscopy   (SEM)   and   Energy-­
Dispersive  X-­Ray  Spectroscopy  (EDX)  each  sample  was  mounted  upon  a  carbon  tab.  
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Those  samples  for  SEM  only  were  sputter-­coated  with  Au  using  a  Polaron  SC7640  
SEM  Coating  System,  800  V  for  30  seconds  at  5  mA.    
SEM  was   used   to   investigate   the  morphology   and  particle   size   of   each   sample’s  
structure.  Using  a  Supra  40VP  (Carl  Zeiss  Ltd.)  and  the  software,  SmartSEM.  
EDX  was  conducted  on  all  ZnO@ZIF-­8  samples  using  an  Apollo  40SDD  (EDAX  Inc.),  
using   the  Genesis   software.   This  measured   elemental   compositions   of   the  metal  
oxide  composites  and  potential  Ag  concentrations,  which  may  have  remained  from  
previous  amalgamation.  For   each  element  present,   the  mean  percentage  weight  
was  derived  from  five  random  areas  per  sample.    
X-­Ray  diffraction  (XRD)  patterns  for  each  crystalline  sample  were  obtained  using  a  
PANalytical  X’Pert  diffractometer  fitted  with  a  PixCEL  1-­D  detector  using  a  Cu  anode  
(kα1  λ=  1.5406  Å)  with  the  generator  set  at  40  mA,  40  kV.  Flat  powder  samples  
were  prepared  and  measured  in  reflection  geometry  in  the  range  5-­120°  2q  with  a  
step  size  of  0.013°  2θ  and  a  collection  time  of  118  s/step  using  automatic  divergence  
and  anti-­scatter  slits  with  an  observed  length  of  5.0  mm.  Data  was  processed  using  
HighScore  Plus  version  4.7  (PANalytical  BV,  Delft,  Netherlands,  2017).  
Nitrogen   adsorption-­desorption   measurements   were   taken   at   -­196°C,   using   a  
Micromeritics  ASAP  2020  surface  area  analyser.  Samples  were  degassed  at  200°C  
overnight,  prior  to  analysis.  Using  the  BET  equation  in  the  0.05-­0.3  range  of  relative  
pressures,  and  the  BJH  (desorption  branch  of  the  isotherm)  method,  specific  surface  
areas  and  pore  size  distributions  were  calculated.  Total  pore  volumes  (Vtotal)  were  
obtained   from   the   volume   adsorbed   at   a   relative   pressure   of   0.99,   whereas  
micropore  volumes  (Vµ)  and  BET  surface  areas  (SBET)  were  determined  from  t-­plot  
analysis.    
  
2.3.   Antimicrobial  Testing  of  ZIF-­8  and  ZnO@ZIF-­8  
Antimicrobial  tests  of  each  selected  sample  were  conducted  as  detailed  below.    
  
2.3.1.  Maintenance  and  standardization  of  microorganisms  
Escherichia  coli  (E.  coli,  NCTC  9001)  was  maintained  on  Luria-­Bertani  (LB)  agar  (BD,  
Sparks,  MD),  at  4°C.    
For  the  ‘minimum  bactericidal  concentration  assay’  (MBC),  a  single  colony  of  E.  coli  
was  inoculated  into  25  mL  of  Luria-­Bertani  (LB)  broth  and  grown  22±1  hours  at  37°C  
with  agitation  (180  rpm).  Cells  were  then  harvested  by  centrifugation  (3600  rpm,  
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10  minutes)  and  resuspended  in  LB  broth  to  an  optical  density  of  0.025  at  600  nm,  
using  a  Jenway  6305  Spectrophotometer,  UK.    
For   the   ‘measurement   of   antibacterial   activity   on   composite   samples’   assays,   a  
single  colony  of  E.  coli  was  inoculated  into  25  mL  of  Luria-­Bertani  (LB)  broth  and  
grown  22±1  hours  at  37°C  with  agitation  (180  rpm).  Cells  were  then  harvested  by  
centrifugation  (3600  rpm,  10  minutes)  washed  once  in  0.85%  NaCl  (Oxoid,  UK)  and  
resuspended  in  0.85%  NaCl  (Oxoid,  UK)  to  an  optical  density  of  0.025  at  600  nm.    
For  both  assays,  an  average  suspension  concentration  of  2.8x107  CFU  mL-­1  resulted.  
  
2.3.2.    MBC  assay  
The  commonly  used  MBC  assay  determines  the  minimum  amount  of  an  antimicrobial  
compound   that   is   sufficient   to   reduce   bacterial   survival   in   a   planktonic   (that   is,  
bacteria   floating   as   single   cells   in   water)   culture.141   For   the   purpose   of   this  
investigation,  the  MBC  obtained  was  considered  to  be  the  lowest  concentration  of  a  
compound  able  to  kill  all  cells  present  (i.e.  zero  cells  were  recovered  on  fresh  agar).  
Suspensions   of   the   following   compounds,   at   concentrations   of   4  mg  mL-­1,   were  
repeated  technically  in  triplicate,  and  then  biologically  repeated  once,    Table  1.  
  
Table  1:  Sample  key  for  materials  tested  by  MBC  assays.  
Sample  Number   Material  
1   ZIF-­8  from  MeOH  synthesis  
2   ZIF-­8  from  MeOH  synthesis  (Calcined)  
3   ZnO@ZIF-­8  derived  from  Sample  1  
4   ZnO@ZIF-­8  derived  from  Sample  2  
5   ZnO@ZIF-­8  derived  from  Sample  2  
(Calcined)  
6   ZIF-­8  from  TEA  (3cm3)  synthesis    
7   ZIF-­8   from   TEA   (3cm3)   synthesis  
(Calcined)  
8   ZnO@ZIF-­8  derived  from  Sample  7  
9   ZIF-­L  
10   ZnO@ZIF-­L  derived  from  Sample  9  
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Each  sample  was  suspended  in  sterile  distilled  water  to  a  concentration  of  4  mg  mL-­
1.   A   doubling   dilution   was   performed   to   a   concentration   of   7.63x10-­6   mg  mL-­1,  
leaving   a   100   µL   volume   of   each   dilution   in   its   corresponding   well.   100   µL   of  
standardised  E.  coli  in  LB  broth  (as  described  above)  was  added  to  each  well  and  
each  96-­well  plate  was  covered  with  a  lid.  These  were  incubated  static,  at  37°C  for  
18  hours.  As  a  negative  control,  100  µL  of  culture  plus  100  µL  of  sterile  distilled  
water  was  used.  Following  incubation,  20  µL  aliquots  were  taken  from  each  well,  
pipetted  onto  quartered  LB  agar  plates,  and  spread  evenly  prior  to  static  incubation  
(37°C)  for  a  further  24  hours.  The  MBC  was  recorded  as  the  lowest  concentration  
at  which  growth  was  prevented.  In  total,  six   technical   repeats  were  conducted  -­  
three  for  each  biological  repeat.  
  
2.4.   Synthesis  of  Composite  Samples  
The   best   performing   samples   from   MBC   assay   results   were   selected   for  
incorporation  into  silicone  composite  samples,  alongside  their  ZIF-­8  or  ZnO@ZIF-­8  
counterparts.  Prior  to  use,  each  of  these  were  dried  in  an  oven  at  100°C,  overnight.  
Composite  samples  were  prepared  using  M511  maxillofacial  material  (Technovent,  
UK).  Composites  contained  a  mixture  of  29.33  g  Part  A  (Silicone  polymer  with  Si-­H  
groups)  and  3.66  g  Part  B  (vinyl  functionalised  dimethyl  silicone  polymer,  plus  Pt  
catalyst).  This  resulted  in  a  ratio  of  8:1,  Part  A:Part  B.  It  should  be  noted  that  all  
commercial   silicone   elastomers   contain   fumed   silica   reinforcement.   The   M511  
contains   a   small   amount   of   fumed   silica   reinforcing   filler,   without  which,   tensile  
strength  would  be  almost  uselessly  low.  When  incorporating  ZIF  materials,  1.32  g  
(4   wt.%)   was   added   and   stirred   under   vacuum   for   5   minutes   using   Multivac   4  
(Degussa  AG,  Germany).  The  uncured  composite  was  then  allowed  to  settle  under  
vacuum,  prior  to  spreading  into  a  13  cm  x  13  cm  x  0.2  cm  metal  mould,  positioned  
atop  a  polytetrafluoroethylene  (PTFE)-­coated  sheet,  using  a  pallet  knife.  This  was  
then  placed  upon  a  vibrating  table  for  10  minutes.  All  air  bubbles  produced  were  
burst  using  a  scalpel  and  a  second  PTFE  sheet  was  used  to  sandwich  the  mould.  
This  was  then  cured  for  1  hour  at  100°C,  under  10  Ton,  using  a  Bradley  and  Turton  
hydraulic  press.  The   sample  was  allowed   to   cool   to   room   temperature  and   then  
eased  out  of  the  mould  gently.    
  
2.5.   Assessment  of  ZIF  Particle  Dispersion  Quality  
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The  dispersion  quality  of  ZIF-­8  and  ZnO@ZIF-­8  particles  was  assessed  at  two  size  
scales;;  macro-­dispersion  was  assessed  qualitatively  using  digital  images,  whilst  the  
micro-­dispersion  quality  was  assessed  using  the  SEM  images  of  the  freeze-­fractured  
surfaces  taken  at  50,000  times  magnification.    
  
2.5.1.  Macro-­dispersion  
Digital   images   were   obtained   using   a   Samsung   Galaxy   S6   Edge   mobile   phone  
camera,  clamped  above  a  black  tile  for  consistent  height.  1.2  cm  x  1.5  cm  coupons  
of  each  composite  sample  were  photographed  against  the  black  tile,  alongside  two  
perpendicular  rules  for  scale.  Macro-­dispersion  qualities  of  the  ZIF-­8  particles  were  
observed  from  these  images.  
  
2.5.2.  Micro-­dispersion  from  freeze-­fracture  analysis  
The  micro-­dispersion  of  the  ZIF-­8  particles  was  assessed  by  SEM  imaging  of  freeze-­
fractured  surfaces,  prepared  as  follows:  A  1  cm  x  1  cm  x  0.1  cm  coupon  was  cut  
from  each  composite  sample,  as  well  as   from  a  control  sample  of  cured,  unfilled  
matrix.   Each   coupon   was   then   frozen   in   liquid   nitrogen   and   fractured   into   two  
pieces.  The  fractured  coupon  was  then  mounted  to  a  tab  and  was  sputter-­coated,  
allowing  the  cross-­sectional  area  of  the  fractured  surface  to  examined  using  SEM.  
Instrumentation  and  sputter-­coating  conditions  remained  as  stated  in  Section  2.2.    
  
2.6.   Composite  Properties  
  
2.6.1.   Percent  mass  hexane  swelling  and  extractables  
The  matrix  crosslink  density  is  confounded  with  filler-­matrix  interactions  -­  the  fillers  
existing  as  both  fumed  silica  and  the  incorporated  ZIFs.  Whilst  these  were  known  
to   affect   the   composites’   hexane   swelling   behaviour,   further   investigation   was  
considered  worthwhile  due  to  evidence  that  ZIFs  affected  curing  characteristics  of  
M511  (see  Section  3.3.).  This  presented  so  significant,  that  an  increase  in  crosslinker  
volume  was  necessary.  Thus,  it  was  anticipated  that  some  fractions  of  the  matrix  
may  not  be  crosslinked.    
The  amount  of  crosslinked  polymer  was  determined  using  the  hexane  extractables  
content.   Hexane   was   the   chosen   solvent   due   to   its   close   match   to   the   Hansen  
Solubility  parameter  of  polydimethylsiloxane  (14.9  dd  and  15.1  dd,  respectively).  
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Hexane  (Fisher)  swelling  measurements  were  carried  out  on  the  composite  samples  
under  ambient  conditions.  Sample  coupons,  with  dimensions  of  1  cm  x  1  cm  x  0.1  
cm   were   used.   Each   coupon   was   weighed   both   before   and   after   immersion   in  
hexane  for  24  hours.  Each  vessel  was  covered  throughout  the  immersion  time,  in  
order   to  prevent  solvent  evaporation.  Excess  hexane  was  removed  from  samples  
using   filter   paper   before  weighing.   The   degree   of   swelling  was   calculated   using  
equation  1.0.    
  𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔	  𝑑𝑒𝑔𝑟𝑒𝑒	  (%) = 	  /01234	  564078/01234	  906:70/01234	  906:70 	  𝑥	  100        (1.0)  
  
Each  coupon  was  then  dried  overnight  in  an  oven  at  70°C,  prior  to  re-­weighing  and  
determination  of  the  hexane  extractables  content.  The  equation  2.0  was  used.    
  𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑎𝑏𝑙𝑒𝑠	  𝑐𝑜𝑛𝑡𝑒𝑛𝑡 = 	  F5GG	  906:708F5GG	  :6	  H710H	  G5FIJ0F5GG	  906:70 	  𝑥100      (2.0)  
  
  
2.6.2.    Tensile  testing  
Tensile  tests  (N=5)  were  conducted  at  room  temperature  using  a  Hounsfield  H10KS  
tensometer  running  Qmat  5.52  software.  The  instrument  was  fitted  with  a  100  N  
load  cell  and  laser  extensometer.  Crosshead  speed  was  500  mm/min.  BS903  type  2  
dumb-­bell  specimens  with  a  width  of  4.0±0.1  mm  were  cut  from  each  ~1  mm  thick  
composite  sheet.  Test  piece  thickness  was  measured  using  a  dial  gauge.    
  
Average  stress-­strain  curves  were  plotted  using  Microsoft  Excel,  for  each  material  
using  the  raw  strain  and  force  data  for  each  sample.  Values  of  stress  were  calculated  
via  using  equation  3.0.  
  𝑆𝑡𝑟𝑒𝑠𝑠	  (𝑀𝑃𝑎) = M:7N0	  (O)P705	  (FFQ)               (3.0)  
  
Values  of  tensile  strain  were  provided  by  the  QMAT  5.52  software  and  were  present  
in  the  obtained  raw  data.  Estimated  values  of  Young’s  modulus  were  determined  
using  linear  regression  from  the  initial  linear  region  of  the  stress-­strain  curves.  The  
linear  region  varied  from  between  0  to  10%  and  0  to  30%.  The  Young’s  moduli  
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were  determined  for  all   five  replicates,  with  the  average  and  standard  deviations  
deduced.   Values   of   average   tensile   strength   and   elongation   at   break   were   also  
determined  from  the  computer  software  generated  values.    
  
  
2.7.   Antimicrobial  Testing  of  Composite  Samples  
  
2.7.1.    Measurement  of  antibacterial  activity  on  composite  samples  
The  antibacterial  activity  of  each  composite  sample  was  tested  following  an  adapted  
protocol   of   the   BS   ISO   22196:2011.   This   protocol   is   the   current   international  
standard   for   evaluating   the   biocidal   activity   of   antibacterial-­treated   plastics   and  
other  non-­porous  surfaces  of  products,  such  as  the  M511  maxillofacial  silicone  used  
in  this  study.  Time  points  for  sampling  were  conducted  at  0,  3,  8  and  24  hours.  For  
each  composite,  three  1  cm  x  1  cm  x  0.1  cm  coupons  were  prepared  per  time  point.  
These  were  cut  to  size  using  a  scalpel  and  rule  and  sterilised  using  absolute  ethanol.  
Each  of   these  were   then   inoculated  with  10  µL  of  washed  and  standardized  cell  
suspension  (comprised  from  LB  Broth),   then  covered  gently  with  a  1  cm  x  1  cm  
piece  of  polyethylene  (PE)  (SLS,  Nottingham).  Triplicates  of  covered  coupons  were  
carefully  positioned  in  petri  dishes  then  incubated  at  37°C  within  a  lidded  container,  
lined  with  moistened  paper  towels,  to  create  conditions  of  >90%  humidity.  At  the  
appropriate   time   points,   each   sample   coupon   and   its   attached   PE   sheet   was  
immersed  in  10  mL  neutralising  buffer  (15  g  Tween80  [Sigma-­Aldrich,  Dorset]  and  
30  g  Soya  Lecithin  [Optima  Healthcare  Lecithin,  Holland  and  Barratt,  UK.]  dissolved  
in   1   L   distilled   water),142   then   vortex-­mixed   for   30   seconds.   This   ensured   the  
removal  of  both  the  PE  sheet,  and  most  of   the  cells   from  the  composite  and  PE  
surfaces,   into   the   liquid.   Use   of   the   neutralising   buffer   prevented   any   further  
bactericidal   action   from   the   appropriate   time   point.   The   resulting   bacterial  
suspension  was  diluted  10-­fold  (1  mL  into  9  mL  of  sterile  physiological  saline),  seven  
times,  to  a  concentration  of  10-­7  of  the  original  suspension.  20  µL  of  each  dilution  
was  then  pipetted,  in  duplicate,  onto  quartered  LB  agar  plates  and  spread  evenly  
across  the  allocated  agar  surface  using  a  loop.  Plates  were  incubated  for  18  hours  
at  37°C.  The  CFU  mL-­1  was  then  calculated  following  resultant  colony  counts.  All  
samples  were  duplicated,  and  the  experiment  was  repeated.  
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2.8.  Metal  Release  Testing  in  Artificial  Urine    
  
For  each  composite  material  (including  the  control),  a  1  cm  x  1  cm  x  0.1  cm  coupon  
was   submerged   in   10   cm3   artificial   urine   and   sealed   within   a   sterile   universal  
container.   This   was   incubated   at   37°C,   remaining   stationary   for   85   days.   The  
coupon   was   removed   by   filtration,   then   Inductively   Coupled   Plasma   Mass  
Spectrometry  (ICP-­MS)  analysis  was  conducted  on  the  filtrate  remaining.    
ICP-­MS  was  conducted  as  follows,  using  an  iCAP6300  DUO  (Thermo  Scientific),  with  
the  software  package,  Qtegra.  A  solution  of  artificial  urine  was  prepared  using  the  
following:  0.20  g  KCl,  8.00  g  NaCl,  1.14  g  Na2HPO4  and  0.20  g  KH2PO4.  Deionised  
H2O  was  then  added  to  form  a  total  volume  of  1.00  Litre.  The  pH  of  the  solution  
was  adjusted  using  HCl  and  NaOH,  resulting  in  a  final  pH  of  7.75.143  
For  each  composite   sample,   corresponding  crystalline  powder   samples  were  also  
tested.  Solutions  of  each  ZIF-­8  and  ZnO@ZIF-­8  (4  mg/mL),  were  made  using  10  
cm3  artificial  urine  and  sealed  within   sterile   universal   containers.   Likewise,   these  
were  incubated  stationary  for  85  days  at  37°C.  The  sediment  was  then  removed  by  
filtration   and   ICP   analysis   of   the   filtrate   was   conducted   as   above.   For   further  
analysis,   each   crystalline   sediment   was   recovered   and   air-­dried   prior   to   XRD  
investigation.    
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CHAPTER  3:  RESULTS  AND  DISCUSSION  
  
3.1.  Synthesis  of  ZIF-­8    
  
3.1.1.  Synthesis  in  organic  medium    
ZIF-­8  samples  were  prepared  in  the  presence  of  three  different  organic  solvents;;  
methanol,   industrial   methylated   spirit   and   N,   N-­dimethylformamide,   following  
synthesis  routes  adapted  from  Cravillon  et  al.90  This  enabled  investigation  into  how  
the  variation  of  organic  solvent  affected  the  purity,  crystallinity  and  morphology  of  
ZIF-­8.    
In  contrast   to  other  syntheses  routes  of  nanoscale  carboxylate-­based  MOFs,   this  
simple   organic   method   did   not   require   any   activation   or   auxiliary   stabilising   by  
means   of   heating   or   microwave/   ultrasound   irradiation.144-­146   Instead,   a   room  
temperature  synthesis  was  conducted,  which  required  the  addition  of  excess  Hmim  
to  the  zinc  source,  Zn(NO3)•6H2O,  in  each  organic  solvent.  When  using  methanol,  
nanocrystals   rather   than   larger   microcrystals   were   formed,   similarly   detailed   by  
Huang  et  al.  and  Park  et  al.   in  previous  studies.60,  147  XRD  and  SEM  analysis  was  
conducted  on  the  resultant  samples.  Corresponding  XRD  patterns  are  illustrated  in  
Fig.  4  and  SEM  images  are  depicted  in  Fig.  5.    
  
Figure   4:   XRD  patterns   of   ZIF-­8   samples   prepared   using   (a)  methanol  
(MeOH),   (b)   industrial   methylated   spirit   (IMS)   and   (c)   N,   N-­
Dimethylformamide  (DMF).  



















Comparing   these   patterns   to   those   reported   by   Cravillon   et   al.   confirmed   that  
synthesis  routes  using  MeOH  and  IMS  both  resulted  in  the  formation  of  pure,  single-­
phase  ZIF-­8.90  XRD  patterns  of  the  DMF  synthesized  sample  however,  highlighted  




Figure  5:  SEM  images  of  ZIF-­8  samples  prepared  with:  (a)  MeOH,  (b)  IMS  
and  (c)  DMF  solvents.  
  
The  SEM  images  clearly  showed  round,  uniform  crystals  of  ZIF-­8  from  MeOH-­based  
synthesis  (Fig.  5a)  each  of  ~60  nm  in  size.  These  were  slightly  larger  than  those  
reported   by   Cravillon   et   al.   measuring   ~40   nm,   however   similar   rhombic  
dodecahedron  ZIF-­8  nanocrystals  were  obtained.90  In  contrast,  Fig.  5b  displayed  
slightly  larger,  irregular  particles  following  synthesis  using  IMS.  Peak  widths  in  the  
XRD  patterns  remain  closely  similar  between  syntheses  with  MeOH  and  IMS,  and  
the  SEM  images  suggest  crystallite  sizes  akin  to  one  another.  However,  aggregates  
are   clearly   presented   by   the   SEM   image,   in   the   case   of   the   IMS   solvent.  
Furthermore,   Fig.   5c   clearly   showed   the   presence   of   other   unknown   crystal  
structures  following  reactions  using  DMF.  Impurities  highlighted  by  the  XRD  patterns  
above,   were   accredited   to   these   irregular   structures.   For   these   reasons,   only  
samples  produced  using  MeOH  as  the  organic  solvent  were  carried  forward  for  post-­
synthesis  modification  and  further  studies.  
  
3.1.2.  Synthesis  in  aqueous  medium  
ZIF-­8  was  also  prepared  in  aqueous  medium  to  reduce  the  use  of  large  amounts  of  
organic  solvents  as  well  as  the  amount  of  Hmim.  Triethylamine  (TEA),  was  added  
to   the   synthesis   solution   to   facilitate   the   ZIF-­8   formation.   In   accordance   with  
previous  results,  adjusting  the  ratio  of  TEA  within  the  reaction  mixture  effected  the  
a b c
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size  of  ZIF-­8  particles  produced.87  XRD  patterns  of  samples  prepared  with  varied  
amounts  of  TEA  are  shown  in  Fig.  6.    
  
Figure  6:  XRD  patterns  of  ZIF-­8  samples  prepared  using  1  cm3  -­  4  cm3  TEA  
(a-­d,  respectively).  
  
Comparisons  of  these  peaks  with  those  previously  reported,  confirmed  the  presence  
of  pure  ZIF-­8  in  samples  made  with  3  cm3  and  4  cm3  TEA.90  Samples  formed  using  
2  cm3  TEA  showed  that  formation  of  ZIF-­8  was  successful,  though  additional  peaks  
suggested   the   presence   of   impurities.   A   reduction   of   TEA   to   1   cm3   however,  
presented  XRD  patterns  which  were  absent  of  ZIF-­8’s  characteristic  peaks.  This  was  
supported  by  the  literature,  which  purported  three  reasons  for  low  TEA/total  molar  
ratio  (0  to  0.002)  restricting  the  synthesis  of  ZIF-­8.87  Firstly,  a  low  ligand  to  metal-­
salt   ratio  may   result   in   intergrowth  hinderance.148  Secondly,   insufficient   ratios  of  
Hmim  in  the  solution  may  have  impeded  crystal  growth  and  reduced  the  reaction  
rate,  and  finally;;  such  low  TEA/total  molar  ratio  was  insufficient  to  deprotonate  the  
Hmim,   producing  more   reactive   sites   on   the   ligands.   Reactions   with   Zn2+   were  
therefore  obstructed.87  Due  to  differences   in  the  patterns  achieved  showing  pure  
ZIF-­8  and  those  obtained  from  synthesis  with  1  cm3  and  2  cm3  TEA,  these  particular  
synthesis  methods  were  disregarded  from  further  study.    
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SEM   analysis   revealed   a   decrease   in   crystal   size   as   the   amount   of   TEA   used  
increased.   This   is   detailed   in  Fig.  7   and   confirmed   in   previous   reports.87   These  
further  informed  the  preferred  TEA  volume  (cm3)  required  for  ZIF-­8  formation.    
  
Figure  7:  SEM  images  from  aqueous  ZIF-­8  synthesis  using  (a)  1  cm3  TEA,  
(b)  2  cm3  TEA,  (c)  3  cm3  TEA  and  (d)  4  cm3  TEA.  Scale  bars  indicate  200  
nm.  
  
As  depicted  above  (Fig.  6  and  Fig.  7a),  aqueous  synthesis  using  only  1  cm3  TEA  
did  not  result  in  the  formation  of  ZIF-­8.  Instead,  mixed-­phase  crystals  were  shown  
-­   some   2D,   elongated   and   ‘leaf-­like’   in   shape.   Comparisons   with   the   literature  
confirmed  that  these  were  ZIF-­L  structures,  as  opposed  to  ZIF-­8.59  Since  these  were  
formed  from  the  same  precursor  materials  but  resulted  in  such  different  crystal  sizes  
and  morphologies,  ZIF-­L  samples  were  also  carried  forward  for  further  studies.  
  
Structures   displayed   in  Fig.   7b,   showed   irregularities   and   structural   defects,   as  
supported  by  XRD  patterns  in  Fig.  6.  Due  to  this,  samples  produced  using  2  cm3  
TEA  were  eliminated  from  future  investigation.  Furthermore,  Fig.  7c  indicated  the  
presence  of  noticeably  larger  ZIF-­8  crystals  (up  to  250  nm)  compared  to  those  in  
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Fig.  5a.  Despite  confirming  both  samples  formed  using  3  cm3  and  4  cm3  TEA  as  
ZIF-­8,  more   uniform   crystals  were   shown  by   those  made  using   3   cm3  TEA.   The  
trend  in  particle  size  to  TEA/total  molar  ratio,  remained  a  consequence  of  greater  
amounts  of  TEA,  which  promoted  more  nuclei  formation  via  the  deprotonation  of  
Hmim.  Rapid  reactions  between  Zn2+  and  Hmim-­  encouraged  the  formation  of  small  
particles.85   Investigations  by  Nordin  et  al.   surmised   that   the  highly   concentrated  
synthesis  solution  led  to  rapid  crystal  formation  with  irregularities  arising  from  the  
addition  of  TEA.87  TEA  deprotonates  the  organic  ligand  during  ZIF  formation,  and  
thus  controls  crystal  growth  and  particle  size.59,  87    
  
Additional   analysis   of   ZIF-­8   samples   prepared   with   different   TEA   volumes   was  
conducted  using  nitrogen  adsorption  data.  Corresponding  BET  surface  areas  were  
calculated  and  listed  in  Table  2.      
  
Table  2:  BET  surface  areas  of  ZIF-­8  from  organic  and  aqueous  synthesis  
routes.    
ZIF-­8  Synthesis  Route   Surface  Area  (m2/g)  
Organic  using  MeOH   1110  
Aqueous  using  1  cm3  TEA   58  
Aqueous  using  2  cm3  TEA   437  
Aqueous  using  3  cm3  TEA   492  
Aqueous  using  4  cm3  TEA   478  
  
Values  in  Table  2  are  significantly  lower  than  those  reported  by  routes  of  similar  
organic  synthesis  (obtaining  >1000  m2/g).90  Low  surface  areas  for  the  aqueously  
synthesised   ZIF-­8   suggested   occluded   TEA   molecules   and/or   unreacted   Hmim  
within   the   microporous   framework.   By   calcining   these   samples,   such   guest  
molecules   were   evacuated.   The   sample   prepared   with   3   cm3   TEA   showed   the  
highest   surface  area,  and   this   sample  was  heat-­treated  at  200°C   to   remove   the  
occluded  TEA  molecules.  The  surface  area  of  this  sample  following  heat-­treatment  
increased   to   1084  m2/g   confirming   the   successful   opening   of   the   ZIF-­8   porous  
structure.   In   addition,   XRD   patterns   of   this   sample   before   and   after   the   heat  
treatment   (Fig.   8)   showed   the   preservation   of   the   ZIF-­8   structure   after   heat-­
treatment,  and  an  increase  in  the  intensities  of  the  ZIF-­8  XRD  peaks,  in  accordance  
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with  the  surface  area  results.  
  
Figure  8:  XRD  patterns  of  ZIF-­8  prepared  using  3  cm3  TEA:  (bottom)  as-­
made  and  (top)  heat-­treated  at  200°C.  
  
3.1.3.  Post-­synthetic  modification  of  ZIF-­8    
The  ZIF-­8  prepared   in  MeOH  (ZIF-­8  (MeOH)),  and   in  an  aqueous  medium  in  the  
presence  of  3  cm3  TEA  (ZIF-­8  (TEA)),  were  selected  for  post-­synthesis  modification  
with   AgNO3   to   prepare   ZnO@ZIF-­8   structures.   To   minimise   variations   in   the  
properties  of  the  samples  during  microbiology  experiments,  samples  were  prepared  
in  small  batches  and  mixed  together  to  obtain  a  large  homogeneous  batch  of  each  
sample.   These   were   used   in   all   further   studies.   Considerably   more   reactions   in  
MeOH  were  required  to  obtain  similar  amounts  of  ZIF-­8  as  achieved  from  aqueous  
methods,   since   yields   were   reported   to   be   50%   and   90%,   respectively.87,   90  
Following  this,  samples  of  ZIF-­8  from  both  routes  were  post-­synthetically  modified  
to  obtain  ZnO@ZIF-­8.  These  were  characterised  and  further  tested  alongside  ZIF-­8  
in  minimum  bactericidal  concentration  (MBC)  assays.    
Half  of  the  ZIF-­8  (MeOH)  and  ZIF-­8  (TEA)  batches  prepared  were  post-­synthetically  
treated  with  silver  nitrate  solution  to  obtain  ZnO@ZIF-­8  (MeOH)  and  ZnO@ZIF-­8  
(TEA)  samples  as  described  in  previous  studies.9,  95  The  treatment  resulted  in  the  
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spontaneous  formation  of  ZnO  nanorods  within  the  ZIF-­8  material.  Figs  9  and  10  
show  XRD  patterns  of  ZIF-­8  and  ZnO@ZIF-­8  batches,  synthesised  with  MeOH  and  
TEA,  respectively.  
  
Figure   9:   XRD   patterns   of   (a)   batch   ZIF-­8   sample   prepared   using  
methanol   and   (b)   the   corresponding   ZnO@ZIF-­8   sample.   The   asterisk  
indicates  ZnO  XRD  peaks  (reference  pattern  96-­900-­4182).  
  
























Figure  10:  XRD  patterns  of  (a)  batch  ZIF-­8  sample  prepared  from  the  3  
cm3  TEA  system  and  (b)  the  corresponding  ZnO@ZIF-­8  sample.  
  
In  Fig.  9,  peaks  corresponding  to  the  presence  of  ZnO  were  detected  in  accordance  
with   previous   results.9,   95   The   ZnO   peaks   were   not   detected   in   the   ZnO@ZIF-­8  
sample   prepared   from   ZIF-­8   (TEA)   (Fig.  10).   Post-­synthetic   treatment   of   ZIF-­8  
reduced   the   intensity   of   the   ZIF-­8   peaks   for   both   samples,   which   was   more  
pronounced  for  the  ZIF-­8  (TEA)  sample,  indicating  that  silver  nitrate  treatment  leads  
to   an   inferior   level   of   crystallinity   when   compared   to   ZIF-­8   alone.   SEM   analysis  
depicted   in  Fig.  11   indicated  the  presence  of  ZnO  nanorods   in  both  ZnO@ZIF-­8  
samples   (indicated   by   arrows   in   Fig.   11a).   These   ZnO   nanorods   are   formed  
spontaneously   during   synthesis,   upon   the   surface   of   the   ZIF-­8   crystals.   The  
ZnO@ZIF-­8  (MeOH)  sample  consisted  of  more  rounded  crystals  compared  to  the  
rhombic  dodecahedron  ZIF-­8  (MeOH)  crystals  in  Fig.  5.  ZnO-­nanorods  were  clearly  
depicted   in   the  SEM   image  of  ZnO@ZIF-­8   (TEA)   sample   (Fig.  11b)  despite   that  
they  were  not  detected  by  XRD.  In  addition,  impurities  of  amorphous  material  were  
also   detected   in   this   sample,   which   supported   XRD   patterns   depicting   inferior  
crystallinity  of  that  sample.  


















Figure  11:  SEM  images  of  ZnO@ZIF-­8  samples  prepared  with:  (a)  MeOH,  
(b)  3  cm3  TEA.  
  
EDX  analysis  was  used  to  determine  whether  Ag  impurities  were  present  in  the  post-­
modified   ZIF-­8   samples,   which   would   influence   their   antibacterial   activity   and  
corresponding  spectra  are  shown   in  Figs.  12  and  13.  Peaks  for  C,  N,  O  and  Zn  
concur  with   the  chemical   composition  of  ZIF-­8.  Ag  was  not  detected   in   the  EDX  
spectrum   of   ZnO@ZIF-­8   (MeOH)   (Fig.   11).   However,   Ag   was   present   in   the  
ZnO@ZIF-­8  (TEA)  sample  despite  the  repeated  washing  of  this  sample  suggesting  
a   stronger   interaction   between   silver   nitrate   and   ZIF-­8   (TEA)   (Fig.   12).   These  
results  also  indicate  that  this  post-­synthesis  treatment  procedure  does  not  give  the  





Figure  12:  EDX  spectra  of  ZnO@ZIF-­8  prepared  using  MeOH.  
  
  
Figure  13:  EDX  spectra  of  ZnO@ZIF-­8  prepared  using  TEA.  
  
Analysis   of   batch-­samples   regarding   BET   surface   areas   (m2/g)   and   micropore  
volumes  (cm3/g)  is  detailed  in  Table  3.  
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Table  3:  BET  surface  areas  (SBET),  total  pore  volumes  (Vtotal)  and  micropore  
volumes  (Vmicro)  of  the  four  batch  samples  prepared.  
  
Sample   and  
Synthesis  Route  
SBET  (m2  g-­1)   Vtotal  (cm3  g-­1)   Vµ  (cm3  g-­1)  
ZIF-­8   prepared  
using  MeOH  
1293   0.99   0.58  
ZnO@ZIF-­8  
prepared   using  
MeOH  
1000   1.02   0.42  
ZIF-­8   prepared  
using  TEA  
1280   0.81   0.59  
ZnO@ZIF-­8  
prepared   using  
TEA  
769   0.82   0.32  
  
ZIF-­8   samples   prepared   by   both  methods  were   characterised   by   similar   surface  
areas  and  micropore  volumes  in  agreement  with  the  XRD  results.  The  silver  nitrate  
treatment  resulted  in  a  decrease  in  the  surface  area  and  micropore  volume,  which  
was   more   pronounced   for   the   sample   prepared   from   ZIF-­8   (TEA),   again   in  
agreement  with  the  XRD  results.  The  total  pore  volumes  of  each  ZIF-­8  framework  
increased  marginally   following  silver  nitrate  treatment,  which  could  be  related  to  
the   formation   of   the   ZnO  nanorods.  Nitrogen   adsorption   isotherms   of   the   ZIF-­8  
samples  before  and  after  silver  nitrate  treatment  are  shown  in  Figs.  15  and  16.  All  
isotherms  were  type  I  isotherms  typical  of  microporous  materials  with  a  hysteresis  
loop  at  high  relative  pressures  due  to  interparticle  (textural)  porosity.  The  decrease  
in   the   volume   adsorbed   at   p/p0  <   0.1   for   ZnO@ZIF-­8   samples   is   related   to   the  
inferior  crystallinity  of  the  modified  samples  seen  by  the  decreased  intensity  of  the  
ZIF-­8  peaks  in  the  XRD  patterns  and  also  by  the  lower  micropore  volumes  of  these  
samples.  This  effect  was  more  pronounced  for  the  ZnO@ZIF-­8  (TEA)  sample.  The  
hysteresis   loop   had   a   similar   shape   for   ZIF-­8   (MeOH)   and   ZnO@ZIF-­8   (MeOH)  
samples   (Fig.  15),   indicating  a   similar   interparticle  porosity  as   seen  by   the  SEM  
analysis   (Figs.  11a  and  5a).  The  hysteresis   loop   for  ZnO@ZIF-­8   (TEA)   is   larger  
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compared   to   that   of   ZIF-­8   (TEA)   (Fig.   16),   which   can   be   associated   with   the  
different  morphology  of  these  two  samples  (Figs.  11b  and  7c).    
  
Figure  14:  Nitrogen  adsorption  desorption  isotherms  at  -­196°C  of  (a)  ZIF-­
8  (MeOH)  and  (b)  ZnO@ZIF-­8  (MeOH)  samples.  
  































Figure  15:  Nitrogen  adsorption  desorption  isotherms  at  -­196°C  of  (a)  ZIF-­
8  (TEA)  and  (b)  ZnO@ZIF-­8  (TEA)  samples.    
  
In   this   study,   ZnO@ZIF-­8   samples   adsorb   significantly   less   N2   than   the  
corresponding  ZIF-­8.  This  can  be  explained  by  the  XRD  and  BET  surface  area  data  
in  Figs  9  and  10,  and  in  Table  3,  which  shows  a  reduction  in  the  ZnO@ZIF-­8’s  
surface  area  when  compared  to  samples  of  ZIF-­8.  Greater  structural  collapse  of  the  
ZnO@ZIF-­8  is  also  suggested  by  the  isotherms,  when  compared  to  the  parent  ZIF-­
8.    
Hysteresis   loops  are  commonly  attributed  to  the  thermodynamic  effects,  network  
effects,  or  a  combination  of  both.  With  each  hysteresis  shown  above,  agglomerates  
or  spherical  particles  are  suggested  to  be  arranged  in  a  fairly  uniform  manner  with  
cylindrical  pore  geometries,  thus  indicating  relatively  high  pore  size  uniformity.  Fig.  
14  and  Fig.  15  both  display   larger  hysteresis   loops  for  ZnO@ZIF-­8  than  for   the  
parent   ZIF-­8.   This   is   due   to   the   presence   of   the   ZnO-­nanorods   affecting   the  
intraparticle   (textural)   porosity.   These   loops   are   associated   with   capillary  
condensation  occurring  within  the  mesopores  and  limiting  uptake  over  a  range  of  






























high   relative  pressure   (p/p0).  At  higher  pressures,   the   slopes   show  an   increased  
uptake  of  the  adsorbate  as  the  pores  become  filled.  
  
3.2.   Antimicrobial  Testing  of  ZIF-­8  and  ZnO@ZIF-­8  
  
3.2.1.    Minimum  bactericidal  concentration  assay  
MBC  assays  (Table  4)  highlighted  the  differences  in  antibacterial  potency  of  each  
selected  framework.  For  ZIF-­8,  larger  crystals  with  slightly  lower  BET  surface  areas  
displayed  greater  antibacterial  activities.  These  structures  were  formed  aqueously  
using   TEA   and   presented   more   edge   and   corner   sites   than   ZIF-­8   synthesised  
organically.  For  ZnO@ZIF-­8  samples,  ZnO-­nanorods  are  present  (Fig.  11),  which  
increase  biocidal  activity.9  MBC  assays  of  these  structures  corresponded  to  reports  
by  Stanković  et  al.,  whom  found  that  a  higher  concentration  of  smaller  particles,  
with   a   larger   surface   area,   ensures   more   efficient   antibacterial   behaviour   when  
investigating  properties  of  ZnO  powders.149  It  is  therefore  likely  that  particle  shape  
and  crystalline  structure  have  less  influence  on  biocidal  action  than  size  and  surface  
area.    
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Table   4:   Heat-­mapped   average   MBC   (mg   mL-­1)   values   of   samples  
subjected   to   minimum   bactericidal   concentration   assays,   with   sample  
numbers  corresponding  to  Table  1.    Green  shows  the  lowest  figures,  with  
progression  through  amber  to  red  as  values  increase.  
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The  lowest  concentration  of  ZnO@ZIF-­8  with  the  ability  to  kill  E.  coli  was  Sample  4  
at   0.0228  mg  mL-­1,   derived   from   calcined   ZIF-­8   prepared   using  methanol.   This  
sample  also  presented  the  lowest  values  of  standard  deviation  and  standard  error,  
supporting   the   choice   to   continue   investigations   with   this   sample.   The   lowest  
concentration  of  ZIF-­8  required  to  kill  however,  was  0.0575  mg  mL-­1,  prepared  using  
TEA.   Unfortunately,   this   data   also   presented   the   greatest   values   of   standard  
deviation  and  error,   though  reasons  for  such  varied  results  across  both  technical  
and   biological   repeats   remains   unclear.   It   is   worth   noting   that   this   sample  
demonstrated  a  particularly  strong  static  charge,  which  formed  only  when  ZIF-­8  had  
been  synthesised  using  TEA.  Since  the  mechanism  by  which  the  bacteria  is  killed  is  
unknown,   this   observation   may   have   relevance.   The   average   MBC   (mg   mL-­1)  
demonstrates  that  whilst  ZIF-­8  exhibited  bactericidal  activity,  ZnO@ZIF-­8  formed  
from  its  calcined  ZIF-­8  precursor  had  greater  bactericidal  abilities.  Notably,  ZIF-­8  
and  ZnO@ZIF-­8  compounds  of  different  morphologies,  showed  differences  in  MBCs  
(mg  mL-­1).  This  is  likely  due  to  differences  in  the  polarity,  shape,  size  and  surface  
area  available  for  antimicrobial  action.  When  comparing  ZnO@ZIF-­8  to  ZIF-­8  alone,  
the   presence   of   ZnO   nanorods   explains   the   lowered  MBC.9      Based   on   the  MBC  
results,   ZIF-­L   and   ZnO@ZIF-­L   were   omitted   from   further   studies   due   to   the  
exceptionally   large   average   values   and   ZnO@ZIF-­L’s   reasonably   high   value   of  
standard  deviation.  ZIF-­8  and  ZnO@ZIF-­8  prepared  using  both  organic  and  aqueous  
syntheses  were  carried  forward  for  preparation  of  composite  polymer  samples  and  
antimicrobial  testing  of  the  composite  samples.    
  
3.3.   Silicone  elastomers  containing  ZIF-­8  and  ZnO@ZIF-­8  
  
3.3.1.    Effect  of  ZIF-­8  and  ZnO@ZIF-­8  addition  on  polymer  curing    
During  primary  trials  using  the  manufacturer’s   instructions:  mixing  10:1  Part  A  to  
Part  B  (Technovent,  UK),  and  adding  4  wt.%  ZIF  sample,  polymer  composites  failed  
to  cure  completely.  Despite  following  both  recommended  cure  times  and  conditions  
(room  temperature  and  pressure  for  24  hours  or  1  hour  at  100°C),  neither  method  
produced  usable  results.  Issues  arose  with  incomplete  curing  that  resulted  in  the  
composite   plaques   sticking   to   the   mould.   This   suggested   that   the   MOFs   were  
preferentially  adsorbing  the  manufactured  crosslinker  and/or  the  Pt  based  catalyst.  
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To   resolve   this,   an   alternative   method   of   preparation   was   conducted.   Reactant  
ratios,  mix  times  and  curing  conditions  were  adjusted.  This  led  to  increased  amounts  
of  the  M511  component  containing  the  functionalised  Si  polymer  and  Pt  catalyst.    
PTFE  sheets  also  replaced  the  original  steel   sandwiching  sheets  of   the  mould,   in  
order  to  counter  the  issue  of  any  residual  tendency  for  the  sheets  to  adhere  to  the  
composite  samples.    
  
3.3.2.    Effect  of  adsorbed  gas  release  on  cured  polymer  structure  
Further  complications  arose  during  trials  forming  composite  samples,  whereby  tiny  
air  bubbles   could  be  seen   throughout   the  entire  polymer   sheet.  This  highlighted  
issues  regarding  adsorbed  gas  release  from  the  ZIF-­8  incorporated.  To  rectify  this,  
ZIF-­8  samples  were  dried  overnight  in  an  oven  at  100°C,  prior  to  use.  The  mixing  
and  settling  of  composite  components  was  conducted  under  vacuum,  and  curing  of  
the  composite  samples  was  operated  under  both  heated  and  pressurised  conditions  
by  means  of  the  hydraulic  press.  This  successfully  removed  any  immediately  visible  
porosity,  thus  indicating  that  adsorbed  water  had  been  its  major  cause.    
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3.3.3.    Macro-­dispersion  quality  
Digital   images   illustrated   the   macro-­dispersion,   i.e.   the   dispersion   of   large  
agglomerates,  of  the  ZIF  structures  within  the  cured  silica  matrix  (Fig.  16).    
  
  
Figure   16:   Digital   images   of   cured   composite   samples   containing   (A)  
unfilled  matrix,  (B)  ZIF-­8  prepared  with  MeOH,  (C)  ZnO@ZIF-­8  prepared  
with  MeOH,   (D)  ZIF-­8  prepared  with  TEA  and   (E)  ZnO@ZIF-­8  prepared  
with  TEA.    
  
These  images  display  clear  colour  differences  between  cured  composite  samples,  
containing  ZIFs  prepared  with  MeOH  (Fig.  16  B  and  C)  and  ZIFs  prepared  using  
TEA  (Fig.  16  D  and  E).  Whilst  (Fig.  16B),  is  most  closely-­related  in  colour  to  the  
unfilled   matrix   (Fig.   16A),   notable   agglomerates   of   ZIF-­8   are   present.   When  
compared   to   its  ZnO@ZIF-­8  partner   (Fig.  16C),   the  composite  Sample  B   is   less  
milky/cloudy  with  fewer  agglomerations.  Sample  C  was  found  to  be  the  weakest,  
least  stiff  composite,  with  the  highest  hexane  extractables  (described  within  Section  
3.3.5)  –  this  is  likely  due  particularly  poor  ZIF-­8  particle  dispersion,  as  shown.    
Brown   discolouration   of   samples   prepared   using   TEA   may   originate   from   the  
presence  of  organic  materials  during  calcination.  This   is   further  enhanced  by  the  
presence  of  Ag,  which  is  reduced  during  the  calcination  of  Sample  E.  
It   may   also   be   deduced   that   ZIF-­8s   formed   using   TEA,   show   slightly   better  
dispersion,  however  ZIF-­8  agglomerates  are  obscured  by  the  general  haziness  of  
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ZnO@ZIF-­8  particles  (Fig.  16E).  It  should  be  noted  that  ZIF-­8s  produced  using  TEA  
also  demonstrated  a  strong  static  charge,  whilst  ZIF-­8s  produced  using  MeOH  did  
not.   The   static   charge   on   the   former   particles   indicates   that   they   have   a   more  
hydrophobic  surface  than  the  latter  particles.  Greater  filler  surface  hydrophobicity  
can  lead  to  weaker  filler-­filler  interactions  and  effective  wetting  of  the  filler  surface  
by   the   hydrophobic   silicone   matrix;;   both   these   factors   can   lead   to   more   rapid  
particle  dispersion  and  hence  better  dispersion  quality.150,  151  
  
3.3.4.  Micro-­dispersion  quality  
SEM  images  illustrating  the  micro-­dispersion  (the  dispersion  of  small  aggregates)  of  
ZIFs,   within   freeze-­fractured   surfaces,   are   shown   in   Fig.   17.   It   is   immediately  
evident  that  the  matrix  control  (Fig.  17A)  contains  fumed  silica  -­  the  aggregates  
visible  are  within  the  expected  size  range  of  10-­20  nm.152  
  
  
Figure  17:  SEM  images  of  freeze-­fractured  composite  samples  containing  
(A)   unfilled   matrix,   (B)   ZIF-­8   prepared   with   MeOH,   (C)   ZnO@ZIF-­8  
prepared  with  MeOH,  (D)  ZIF-­8  prepared  with  TEA  and   (E)  ZnO@ZIF-­8  
prepared  with  TEA.  Scale  bar  is  200  nm  (A,  B  and  E)  and  300  nm  (C  and  
D).  
  
These   images  show  minor  differences   in  the  dispersion  quality  of  ZIF-­8  particles,  
regardless  of   their   synthesis   route.  Here,   the  dispersion  of  ZIF-­8  prepared  using  
TEA  (Fig.  17D)  appears  only  marginally  worse  than  that  from  MeOH  preparation  
(Fig.  17B).    
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The   addition   of   the   ZnO   nano-­rods   to   the   ZIF-­8   seemingly   worsens   the   micro-­
dispersion   of   ZIF-­8   formed   via   the   organic  MeOH   route;;   this   is   also   true   of   the  
macro-­dispersion  in  this  pair  of  composites.  Comparison  of  the  effect  of  ZnO  nano-­
rods  on  the  dispersion  of  ZIF-­8  particles  prepared  aqueously  (using  TEA),  however,  
is  hampered  by  the  porosity  produced  (Fig.  17E).  
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3.3.5.   Percent  mass  hexane  swelling  and  extractables  
Average  hexane  swelling  (absorption)  mass  percentages  allowed  an  insight  into  the  
crosslink  density  and  filler-­matrix  interaction  within  the  composites.  Generally,  the  
lower   the   %   swelling,   the   greater   the   crosslink   density   and/or   filler-­matrix  
interaction  (provided  the  majority  of  the  chains  are  crosslinked  into  the  network).    
Without   crosslinking,  and  with  weak  hexane  displaceable   filler-­matrix   interaction,  
the   silicone   polymer  matrix  would   be   completely   soluble   in   hexane.   In   contrast,  
crosslinked  chains  are  insoluble,  due  to  the  size  of  their  network  structure;;  solvent  
molecules  can  solvate  the  chains  in  the  network  (leading  to  the  swelling  effect),  but  
due   to   the   crosslinking   between   the   chains,   cannot   take   individual   chains   into  
solution.  
When  the  interfacial  area  is  high,  and  the  inter-­particle  distance  is  low,  very  strong  
filler-­matrix   interaction   occurs.   This   can   lead   to   adsorption   crosslinking   and  
restricted  matrix  solubility,  whereby  a  single  chain  may  interact  with  more  than  one  
filler   particle.   As   a   result,   entanglements   could   exist   between   loopily   adsorbed  
chains  on  adjacent  filler  particles.    
Considering   experimental   error,   Fig.   18A   shows   that   percentage   mass   hexane  
swelling   levels   of   all   composites   remained   similar   to   the   unfilled  matrix   control.  
Subtle   trends   may   be   observed,   however,   when   considering   both   percentage  
swelling  and  percentage  extractables  content;;  as  ZIF-­8,  and  notably  ZnO@ZIF-­8,  
prepared   using  MeOH,  may  have   had   slightly   lower   crosslink   densities/   levels   of  
filler-­matrix  interaction  than  the  equivalent,  aqueously  synthesised  samples.    
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Figure  18:  Average  hexane  swelling  (A)  and  extractables  content  (B)  (all  
mass  percentages)  of  ZIF  samples  and  unfilled  matrix  control.    
  
The  composite  containing  ZIF-­8  from  MeOH  synthesis  exhibited  the  largest  average  
swelling  percentage,  and  therefore  the  lowest  crosslink  density,  indicating  that  this  
composite  was  likely  the  weakest.  Nonetheless,  these  samples  also  presented  the  
broadest  standard  deviation  and  thus,  were  slightly  less  reliable.    
The   average   percentage   swelling   of   samples   produced   using   TEA   (particularly  
containing  ZIF-­8),  were  almost  identical  to  the  unfilled  control.    
Average  percentage  masses  of  hexane  extractables  content  (Fig.  18B)  remained  
reasonably   identical   across   all   samples   -­   with   the   exception   of   the   organically  
synthesised   (MeOH   prepared)   ZnO@ZIF-­8-­based   composite.   Though   reasonably  
large,   standard   deviations   of   <16.500   were   calculated   for   the   other   composite  
samples,   ranging   from   14.131   –   16.44.   This   demonstrated   close   consistency  
between   the   composites   produced   and  was   expectedly   greater   than   that   of   the  




The   organically   synthesised   (MeOH   prepared)   ZnO@ZIF-­8-­based   composite  
demonstrated  a  9.5%  extractables  content,  as  opposed  to  the  average  ~6%  for  the  
other  samples  and  also  housed  a  significantly  greater  standard  deviation  of  42.654.    
Reduced   crosslinking   within   the   filler-­matrix   interfacial   region   may   occur   if   the  
organically   synthesised   ZnO@ZIF-­8   particle   surface,   deactivates   the   Pt   based  
crosslinking   catalyst.   Should   the   majority   of   the   extractable   material   in   this  
composite   stem   from   the   filler-­matrix   interfacial   region,   then   the   mechanical  
properties  of  this  sample  may  become  poorer.    
The  importance  of  extractables  data  is  highlighted  by  Fig.  18B.  Chains  which  are  
not  chemically  or  strongly  bonded  to  filler  particles  are  extractable.  This  can  lead  to  
reduced   levels   of   swelling  which,   in   isolation,  may   be  mistakenly   interpreted   as  
successful   crosslinking,  e.g.   the  composites   formed  with  ZnO@ZIF-­8   from  MeOH  
synthesis.  If  a  low  level  of  swelling  is  accompanied  by  a  high  extractables  content,  
however,  then  crosslinking  is  likely  to  be  non-­uniformly  distributed  in  the  matrix.  
Whilst   the  majority  of   composite   samples  presented  similar  average  extractables  
content  (%)  to  the  unfilled  matrix,  percentages  from  those  containing  ZnO@ZIF-­8  
from  MeOH  synthesis  were  significantly  higher.    
  
3.3.6.    Tensile  testing  
Average  stress-­strain  curves  for  the  unfilled  matrix  control  and  composite  materials  
are  shown  in  Fig.  19,  with  the  key  mechanical  properties  -­  including  Young’s  moduli  
(stiffness),  summarised  in  Fig.  20.  
Data   compiled   in   Fig.   19,   supports   the   idea   that   the   generally   non-­uniform  
dispersion   of   ZIFs  within   silica   composites   (excluding   that   containing   organically  
synthesised  ZnO@ZIF-­8),   resulted   in  premature   failure,  due   to  the  agglomerates  
acting   as   stress   concentrations/   defects.   Catastrophic   cracks   propagated   from  
these.  Despite  this,  the  TEA  synthesised  ZIF-­8  showed  better  dispersion  than  those  
made  by   the  MeOH   route.  The  end  of  each   line   represents   the  average  point  of  
sample   fracture,   thus   showing   that   the   unfilled   matrix   was   able   to   withstand  
significantly  more  stress  and  strain  than  each  of  the  other  composite  samples.  For  
most,  this  occurred  at  around  520%  elongation  with  stress  levels  of  around  2  MPa.  
Until   this  point,   the  composite   stress–strain   data   remained  similar   to   that  of   the  
unfilled  matrix,   though   subtle   variations   indicated   varied   degrees   of   filler-­matrix  
interaction.    
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In   contrast,   composites   containing   ZnO@ZIF-­8   prepared   using  MeOH,   produced  
significantly  different  stress-­strain  results.  Here,  the  lower  rate  of  stress  increase,  
with   increasing  strain  and  slightly  higher  elongation  at  break,  alluded   to  a   lower  
crosslink   density.   These   conditions   lead   to   a   lower   Young’s  modulus   and   tensile  
strength.  Whilst  reduced  crosslink  density  was  not  supported  by  the  hexane  swelling  
data  (Fig.  18A),  the  observations  can  be  explained  by  the  relatively  high  hexane  
extractables   content   recorded   for   the   ZnO@ZIF-­8-­MeOH   based   composite   (Fig.  
18B).  The  significant  reduction  in  tensile  strength  and  Young’s  modulus  observed  
for   the   latter   composite,   indicated   that   the  majority   of   extractable  material   had  
originated  from  the  filler-­matrix  interfacial  region.    
  
  
Figure   19:   Average   stress-­strain   curves   of   ZIF   samples   versus   unfilled  
matrix  (Av  Str  Control).  
  
Experimental  error  considered,  the  Young’s  modulus  data  (Fig.  20)  indicates  that  
all  composites  (with  the  exception  of  that  containing  ZnO@ZIF-­8  from  MeOH),  had  
broadly  similar  Young’s  moduli  to  the  matrix  control.  When  the  data  is  considered  
alongside  the  filler  dispersion  images  and  the  swelling  data,  however,  corroborative  















Av Str Control ZIF-8 from MeOH Synth.
ZnO@ZIF-8 from MeOH Synth. ZIF-8 from TEA Synth.
ZnO@ZIF-8 from TEA Synth.
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TEA),  have  a  Young’s  modulus  that  is  generally  higher  than  the  matrix  control  and  
other  ZIF-­8  composites  (organically  synthesised  using  MeOH).  It  is  likely  that  this  
TEA   route,   for   aqueous   ZIF-­8   synthesis   provided   a   more   matrix-­compatible,  
hydrophobic   ZIF-­8   particle   surface   which,   in   turn,   resulted   in   better   particle  
dispersion   (Figs.   16   and   17)   and   reduced   hexane   swelling   (Fig.   18A).   The  
composite   containing   ZnO@ZIF-­8   from   MeOH   had   a   significantly   lower   Young’s  
modulus  (and  thus,   reduced  stiffness),  which   likely  manifested  from  non-­uniform  
crosslinking   and  potentially,   substantially   reduced   crosslinking   of   the   filler-­matrix  
interfacial  region.  In  short,  curing  had  not  properly  occurred,  as  supported  by  the  
extractables  content  data.    
Focusing  on  the  elastic  region  of  the  average  stress-­strain  curves  shows  the  data  
collected  more  clearly.  The  percentage  strain  of  each  composite  differs.  Samples  
containing  ZIFs  synthesised  from  TEA  show  the  steepest  curves,  indicating  higher  
Young’s  moduli   -­  exceeding  that  of  the  unfilled  matrix.  When  relating  this   to   the  
average  swelling  percentages  and  extractables  content  (%)  in  Fig.  18,  a  stiffening  
effect  due  to  increased  filler-­matrix  interaction  is  confirmed.  ZnO@ZIF-­8  from  MeOH  
synthesis,  reduces  the  level  of  filler-­matrix  interaction  and/or  the  dispersion  quality,  
as  demonstrated  by  the  noticeably  less  steep  stress-­strain  curve.    
From  Fig.  20  it  can  be  concluded  that  composites  containing  ZIFs  may  be  arranged  
in   the   following   order,   from   best/   strongest   to  worst/   weakest:   ZIF-­8   from   TEA  
synthesis,   ZnO@ZIF-­8   from   TEA   synthesis,   ZIF-­8   from   MeOH   synthesis   then  
ZnO@ZIF-­8  from  MeOH  synthesis.      
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Figure  20:  Average  percentage  elongation  at  break  (A),  tensile  strength  
/MPa  (B)  and  Young’s  modulus  /MPa  (C)  values  of  ZIF  samples  versus  
unfilled  matrix  control.    
  
Similarly,   the   average   swelling   percentage   and   extractables   content   (%),   the  
elongation   at   break   and   the   Young’s   modulus,   gives   information   regarding  
crosslinking  and  filler-­matrix  interaction.  Standard  deviation  error  bars  for  each  of  
the  charts  are  relatively  large,  thus  decreasing  reliability  of  the  data  shown.    
Relative  to  the  unfilled  matrix,  the  addition  of  all  ZIFs  had  little  effect  on  the  Young’s  
moduli   of   samples,   except   when   ZnO@ZIF-­8   from   MeOH   synthesis   was  
incorporated.  Standard  deviation  values  regarding  the  Young’s  moduli  ranged  from  
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0.016   (ZnO@ZIF-­8   from  MeOH)   to   0.064   (ZnO@ZIF-­8   from   TEA).   Each   sample,  
aside  from  that  containing  ZnO@ZIF-­8  from  MeOH,  displayed  a  greater  standard  
deviation  than  that  of   the  control  (0.027).  For  all  composite  samples,   the  tensile  
strength  of  the  material  is  significantly  reduced  in  comparison  to  the  unfilled  matrix,  
likely  due   to  aggregates  and/  or  air  pockets  present   throughout  each  composite  
sample.   These   uneven   aggregates   and   air   pockets   are   also   responsible   for   such  
varied  and  large  standard  deviation  values.  This  is  supported  by  the  data  obtained,  
which  depicts  the  elongation  at  break  (%)  displaying  the  largest  standard  deviation  
(89.9)  upon  the  most  air  pocketed  and  aggregated  sample  (ZnO@ZIF-­8  from  TEA).  
The  standard  deviation  of  this  is  almost  twice  that  of  the  control  (41.48).    
  
3.4.  Antimicrobial  Testing  of  Composite  Samples  
Although   reviewed   and   confirmed   by   the   International   Organisation   for  
Standardization  (ISO)  in  2016,  concerns  have  been  raised  surrounding  the  efficacy  
of  BS  ISO  22196:2011  when  reflecting  environmentally  accurate  conditions.153,  154  
The  need  for  a  better  antimicrobial  testing  method  for  plastics  and  other  non-­porous  
surfaces   remains,   and   analysis   of   the   literature   fails   to   deliver   a   more   suitable  
alternative.153,   154   When   considering   the   urine   flow   of   a   catheterised   patient,  
variations   in   volume   and   output   depend   upon   patient   fluid   status   and   renal  
function.155,  156  Humidity  and  temperature  conditions  of  the  closed  environment  of  
urinary  catheterisation  remains  similar  to  protocol,  however  inoculation  of  patient  
urine  on  the  polymer  surface  would  be  more  frequent  in  practice,  as  the  patient’s  
bladder  is  constantly  relieved.    
  
3.4.1.    Measurement  of  antibacterial  activity  on  composite  samples  
Antibacterial   results   are   shown   in  Fig.  21.  As   expected,   coupons   of   the  unfilled  
matrix  displayed  no  antimicrobial  activity,  depicted  by   the   increase  of  CFUs  over  
incubated  time.  For  each  of  the  4  wt.%  ZIF  composite  samples  however,  bactericidal  
action  was   shown.   Least   effective  was   the   composite   coupons   containing   ZIF-­8,  
aqueously   prepared   using   TEA.   The   numbers   of   recoverable   bacteria   decreased  
from  0-­8  hours,  but  then  remained  static  up  to  24  hours.  This  indicated  that  ZIF-­8  
was  no  longer  actively  killing  the  E.  coli.    
In   comparison,   composite   coupons   containing   organically   prepared   ZIF-­8   (from  
MeOH),  showed  significant  biocidal  activity  after  3  hours  incubation.  At  this  point,  a  
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significant   decrease   of   99.9%   (from  105   to  102  CFU/mL)   recovered   bacteria  was  
shown  from  T0.  Following  8  hours,  no  organisms  were  recovered,  up  to  T24.  Due  
to  this,  ZIF-­8  prepared  using  MeOH,  was  noted  to  be  significantly  better  for  biocidal  
use   within   a   silicone   composite.   Both   forms   of   ZnO@ZIF-­8   composite   coupons  
demonstrated  the  complete  and  retained  kill  of  E.  coli  following  3  hours.  Once  the  
logarithms  of  the  mean  CFUs  were  calculated,  differences  between  those  at  0  hours  
were  not  greatly  significant.  These  were  4.375,  4.801,  4.653,  4.336  and  4.365,  with  
regards   to   the   control,   ZIF-­8   from   MeOH   synthesis,   ZnO@ZIF-­8   from   MeOH  
synthesis,  ZIF-­8  from  TEA  synthesis  and  ZnO@ZIF-­8  from  TEA  synthesis  groups,  
respectively.  As  such,  the  greatest  difference  between  these  values  was  10.18%.  
Furthermore,  logarithms  of  the  standard  deviations  of  each  group  indicated  overlaps  
for  each  mean  CFU  value.  These  were  3.535,  4.380,  4.167,  3.713  and  3.625,  in  the  
respective  order  stated  above.  Despite  incubation  for  24  hours,  the  control  group  
showed  only  an  approximate  1  log  increase.  This  may  be  due  to  a  limited  nutrient  
source,  as  the  aliquot  of  LB  broth  was  not  replenished  throughout  incubation.  
Overall,  ZnO@ZIF-­8  composites  demonstrated  significant  antimicrobial  properties  
against  E.   coli,  when  compared   to   their  precursor  ZIF-­8  composites.  This  was   in  
agreement  with   results   found   by   previous   studies.9  Using   these  materials   in   the  
development  of  urinary  catheters  would  reduce  the  likelihood  of  biofilm  formation,  
since  cells  would  be  unable  to  survive  on  the  catheter  surface.  
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Figure   21:   Average   numbers   of   colony   forming   units   (living   E.   coli,  
CFU/mL)   recovered   from   4   wt.%   ZIF   composite   coupons   and   unfilled  
matrix  (control),  at  set  time  points.    
  
3.5.     Metal  release  testing  in  artificial  urine  
Leaching   of   Zn   and   Ag   from   the   composite   samples   into   artificial   urine,   was  
investigated  following  85  days  incubation.  Data  presented  in  Table  5  was  obtained.  
These   results   are   likely   similar   to   those   expected   from   any   leaching   into   the  
microbiological   testing   media   (LB   broth),   as   neither   solutions   contain   metals  
detrimental  to  the  Zn  of  the  ZIF-­8  structure,  and  both  are  vastly  made  up  of  water.  
The  highest   concentration  of  Zn  present   resulted   from   the  composite   containing  
ZnO@ZIF-­8,   prepared   using   MeOH.   This   averaged   at   302.73   ppb   (0.30   ppm),  
though  no  reference  could  be  found  in  the  literature  to  establish  whether  or  not  this  
was   enough   to   cause   antimicrobial   effects.   However,   composites   containing  
ZnO@ZIF-­8  prepared  using  TEA,  demonstrated  average  concentrations  of  144.05  
ppb  (0.14  ppm)  Ag,  in  agreement  with  EDX  results  (Fig.  13).  As  reported  by  Swathy  
et  al.,  Ag+  released  continuously   from  silver  nanoparticles  (confined   in  nanoscale  
cages)   can   cause   antimicrobial   activity   in   concentrations   as   low   as   50   ppb,   in  
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water.157   Antimicrobial   actions   of   these   composites   must   therefore   be   viewed  
cautiously,  as  antimicrobial  effects  of  Ag  are  now  well  documented.158-­160    
  
Table   5:   Concentrations   of   Zn   and   Ag   detected   from   ICP   analysis   of  
artificial   urine,   following  exposure   to   composite   samples  with   85   days  
incubation.  
Sample  within  Composite  
Average   concentration  
(ppb)  
Zn   Ag  
Unfilled  matrix   61.43   1.13  
ZIF-­8  prepared  using  MeOH   196.53   0.44  
ZIF-­8  prepared  using  TEA   151.89   0.63  
ZnO@ZIF-­8  prepared  using  MeOH   302.73   2.54  
ZnO@ZIF-­8  prepared  using  TEA   79.56   144.05  
  
Similarly,  Table  6  presents  the  average  leaching  concentrations  of  Zn  and  Ag  from  
crystalline  powder  samples,  corresponding  to  those  embedded  within  the  silicone  
elastomers.   Elevated   concentrations   of   both   Zn   and   Ag   were   detected   from   all  
samples  compared  to  results  shown  in  Table  5.  Most  notably,  ZIF-­8  prepared  using  
MeOH,   presented   the   greatest   average   Zn   concentration   of   2368.88   ppb   (2.37  
ppm),  thus  suggesting  significant  leaching  of  Zn  from  the  ZIF  structure,  however  
ZIF-­8  prepared  using  TEA  also  showed  a  large  increase  in  average  concentration.  
Despite   this,   average   concentrations   of   Zn   present   for   samples   of   ZIF-­8   formed  
using  TEA  and  ZnO@ZIF-­8  from  either  synthesis  route  appeared  to  release  similar  
quantities   of   Zn.   Furthermore,   ZnO@ZIF-­8   prepared   via   both   synthesis   routes  
appeared  to  leach  Ag  indicating  that  some  residual  Ag,  which  was  not  detected  by  
EDX,   was   present   within   the   ZnO@ZIF-­8   (MeOH)   sample   as   well.   The   leaching  
experiments  show  that:  (i)  the  ZIF-­8  (TEA)  samples  showed  higher  stability  towards  
Zn   leaching  compared  to  ZIF-­8  (MeOH)  samples;;  (ii)   this  stability  was  higher   for  
ZnO@ZIF-­8  samples  compared   to  ZIF-­8   samples;;   (iii)   silicone  elastomers   further  
reduced  metal  leaching  from  the  ZIF-­8  samples;;  and  (iv)  negligible  concentrations  
of   Ag   were   detected   from   ZnO@ZIF-­8   (MeOH)-­embedded   silicone   elastomers,  
whereas   higher   Ag   concentrations   were   released   from   the   ZnO@ZIF-­8   (TEA)  
composite,  which  contributed  to  its  antibacterial  activity.    
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Table   6:   Concentrations   of   Zn   and   Ag   detected   from   ICP   analysis   of  





Zn   Ag  
ZIF-­8  prepared  using  MeOH   2368.88   71.21    
ZIF-­8  prepared  using  TEA   973.70   42.66  
ZnO@ZIF-­8  prepared  using  MeOH   800.54   2465.29  
ZnO@ZIF-­8  prepared  using  TEA   954.46   7056.00  
  
These  findings  were  supported  by  the  EDX  data  presented  in  Fig.  13,  though  lack  
of   Ag   depicted   by   Fig.   12   is   likely   due   to   Ag’s   concentration   being   below   the  
detection   limit   of   EDX.   It   is   not   exactly   known   why   Ag   is   present   in   the   ZIF-­8  
samples,  as  it  is  not  an  expected  impurity  in  the  zinc  salts  used  in  preparation.  Such  
small   amounts   may   have   been   detected   following   contamination   of   the   ICP-­MS  
equipment,  or  from  the  vials  and  apparatus  used.  The  levels  reported  are  very  close  
to,  and  below,  those  known  to  exhibit  any  antimicrobial  activity.157  Since  Ag  is  not  
a  component  in  the  ZIF-­8  framework,  it  is  unlikely  that  a  continuous  release  of  Ag+  
is  present,  and  so  only  negligible  effects  on  antimicrobial  ability  could  occur,  over  
time.   For   ZnO@ZIF-­8   samples   however,   some   amounts   of   Ag  were   expected   as  
residue  from  silver  nitrate  treatment.  
XRD  was  further  used  to  study  the  degree  of  framework’s  stability  after  the  leaching  
experiments.   XRD   patterns   of   ZIF-­8   prepared   using   MeOH   showed   structural  
differences  between  the  sample,  pre  and  post  incubation  within  artificial  urine.  This  
suggested   that   the   ZIF-­8   framework   had   partially   collapsed   and   that   another  
crystalline   material   had   formed,   thus   explaining   the   increased   average  
concentrations  of  Zn  reported  by  ICP  analysis  (Fig.  22).  Additional  peaks  were  also  
detected  on  the  ZnO@ZIF-­8  (MeOH)  samples,  although  the  main  crystalline  phase  
was  still  ZIF-­8  (Fig.  23).  This  result  confirms  the  ICP  results  that  the  post-­synthesis  
treatment  with  silver  nitrate  stabilised  the  ZIF-­8  structure.  
The  significant  antimicrobial  properties  of  ZnO@ZIF-­8,  shown  by  data  presented  in  
Fig.  21,  are  likely  related  to  the  leaching  of  Zn  and  Ag  ions  present.  The  higher  the  
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bactericidal  activity  of  ZIF-­8  (MeOH)  could  be  explained  by  the  higher  amounts  of  
the  Zn  leached.  Furthermore,  the  highest  activity  of  the  ZnO@ZIF-­8  (TEA)  may  be  
due  to  the  release  of  Ag  from  the  composite.  
  
 
Figure  22:   XRD  patterns  of   the   batch  ZIF-­8   sample  prepared   from   the  
MeOH  system:  (a)  before  and  (b)  after  leaching.    


















Figure  23:  XRD  patterns  of  the  batch  ZnO@ZIF-­8  sample  prepared  from  
the  MeOH  system:  (a)  before  and  (b)  after  leaching.    
  
Figs.  24  and  25  showed  that  the  ZIF-­8  (TEA)  samples  retained  their  structure  after  
incubation  in  artificial  urine,  although  a  certain  decrease  in  the  intensity  of  the  XRD  
peaks  was  detected  following  leaching.  


















Figure  24:  XRD  patterns  of  the  batch  ZIF-­8  sample  prepared  from  the  TEA  
system:  (a)  before  and  (b)  after  leaching.    
 


















Figure  25:  XRD  patterns  of  the  batch  ZnO@ZIF-­8  sample  prepared  from  
the  TEA  system:  (a)  before  and  (b)  after  leaching.    
     

















CHAPTER  4:  CONCLUSIONS  
  
This   project   investigated   the   further   development   of   novel   biocide-­containing  
silicones   for   potential   use   in   urinary   catheters,   for   the   control   of   microbial  
colonisation.  ZIF-­8  and  ZnO@ZIF-­8  were  studied  as  potential  antibacterial  agents,  
against  the  model  bacterium  E.  coli,  with  various  synthesis  routes  considered.  These  
included  both  organic  and  aqueous  methods,   resulting   in   crystal   formations  with  
differing  particle  sizes.  It  was  identified  that  whilst  the  synthesis  route,  organic  or  
aqueous,  had  a  pioneering  effect  on  the  antibacterial  activity,  the  addition  of  ZnO  
nanorods   significantly   increased   the   biocidal   abilities   of   ZIF-­8.   This   supported  
existing   literature,   which   described   the   efficacy   of   ZnO@ZIF-­8   in   relation   to  
nanocrystalline  ZnO  alone.9  The   relationship  between   the  ZIF-­8’s   synthesis   route  
and  antibacterial  activity  has  not  yet  been  discussed  in  existing  literature,  though  
varied   mechanisms   for   ZIF-­8’s   antibacterial   action   have   been   suggested.8,   56,   161  
Whilst   it   is   broadly   accepted   that   ZnO  possesses   antimicrobial   abilities,   and   that  
nanoparticles   offer   greater   efficacies   with   regards   to   their   microparticle  
counterparts,   incorporating   bactericidal   components   with   MOFs   remains   in   its  
infancy.128,  133,  161,  162    
Incorporation   of   the   ZIFs   to   form   silicone   composites   was   achieved,   with   most  
physical   properties   remaining   relatively   similar   to   those   of   the   unfilled   silicone  
matrix,   commonly   used   in   biomedical   applications   today.   The   curing   of   silicone  
elastomers   in   this   study,   required   altered   components   and   conditions   when  
compared  to  those  described  by  Redfern  et  al.9  This  may  be  due  to  slight  differences  
in   the  ZIF-­8  formed  via  different  syntheses,  since  this  study  describes  noticeable  
variations  observed  between  each  silicone  elastomer  formed.  
Leaching   studies   revealed   the   potential   breakdown   of   the   ZIF-­8   framework  
depending  upon  its  synthesis  route,  which  released  Zn2+  ions  into  the  solution.  Since  
these  are  notably  antimicrobial,  different  biocidal  mechanisms  may  depend  upon  
the  ZIF-­8’s  stability,  and  in  turn,  its  route  of  formation.    
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CHAPTER  5:  FUTURE  WORK  
  
Results  and   limitations  highlighted  by   this   study   indicated  the   following  areas  as  
recommendations  for  further  work:  
  
Chemical  investigations  
§   ZIFs  of  other  morphologies  may  be  considered  for  the  tests  examined  above.  
This  may  include  the  use  of  sodium  formate  and/or  n-­Butylamine  for  ZIF-­8  
formation,   as   demonstrated   by   Cravillon   et   al.   Here,   an   excess   of   the  
bidentate   ligand   and   various   simple   auxiliary   monodentate   ligands,   with  
different   chemical   functionalities   (e.g.   carboxylate,   N-­heterocycle,  
alkylamine)  are  applied  to  control/  alter  the  crystal  size.163  
§   Further  analysis  of  leaching  tests  may  be  conducted  to  investigate  whether  
any  harmful  by-­products  are  made  due  to  the  interactions  of  urine  and  the  
MOF  over  time,  particularly  if  the  MOF  is  gradually  degrading.  BET  analysis  
of   the   samples   post-­leaching   would   also   highlight   changes   to   the   ZIFs’  
surface   areas   following   prolonged   urine   exposure.   EDX   analysis   of   the  
recovered,  dried  powders  would  also  provide  compositional  information.  
§   Methods  described  in  this  project  could  be  used  for  further  leaching  tests,  to  
examine  any  differences  between  leaching  in  artificial  urine  and  leaching  in  
LB  broth.  
§   Analysis   of   the   composite   samples   post-­urine   exposure  may   also   indicate  
whether   or   not   salt   crystals   would   form   from   surface   interactions,   thus  
highlighting  potential  issues  regarding  catheter  blockages  and  encrustation.  
§   A  physical  mixture  of  ZnO  nanorods  and  ZIF-­8  should  be  tested  by  the  same  
means  of   this   study,   to   conclude  whether  or  not   this   could  be  a  potential  
candidate   for   the   formation   of   an   antibacterial   composite.   Since   previous  
studies   highlight   the   antibacterial   ability   of   ZnO   nanocrystals   (<100nm)  
alone,  and  this  study  highlights  the  antimicrobial  abilities  of  ZIF-­8  (alone  and  





§   Other  CAUTI-­associated  pathogens  such  as  Klebsiella  pneumoniae,  Proteus  
mirabilis,   Enterobacter   cloacae   and   Staphylococcus   aureus   should   be  
investigated.    
§   Further   tests,   to   collate   evidence   regarding   bacterial   interaction   on   the  
composite  surface,  such  as  adhesion  assays,  crude  viability  testing,  and/or  
24  hour  and  48  hour  biofilm  testing  should  be  conducted.  
§   Alternatives  or  adaptations  to  BS  ISO  22196:2011  should  be  considered  to  
enhance  the  relevance  of  experimental  results  to  those  expected  in  vivo,  e.g.  
composites  should  be  exposed  to  a  continuous  drip  of  live  culture,  simulating  
the  frequent/  continuous  exposure  of  the  material  to  bacteria  and  urine,  in  
catheterised  patients.    
§   Further   investigations   must   be   conducted   in   order   to   investigate   the  
mechanism  by  which  antibacterial  activity  occurs.  
§   Since  composites  may  ultimately  come  into  contact  with  natural  barriers,  e.g.  
the  urethral  epithelium,  further  investigations  must  be  conducted  into  how  
the  MOF  nanoparticles  may  interact.  
§   Furthermore,  toxicity  studies  of  ZIF-­8  and  ZnO@ZIF-­8  must  be  conducted,  
despite  current  evidence  showing  unharmful  characteristics   in  similar  MOF  
structures.164    
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